



KRM AYURVEDA LTD

Annual Report 2025-26



INDEX

S. NO.	PARTICULARS	PAGE NO.
1	COMPANY INFORMATION	3
2	ABOUT THE COMPANY	4
3	CHAIRMAN'S MESSAGE	9
4	JOURNEY & MILESTONES	11
5	BUSINESS & SERVICES	12
6	LIST OF DAY CARE AND HOSPITALS	13
7	OUR PRODUCTS	14
8	OUR SERVICES	15
9	OPERATIONAL FINANCIAL HIGHLIGHTS	16
10	NOTICE OF ANNUAL GENERAL MEETING	17
11	DIRECTORS REPORT	52
12	MANAGEMENT DISCUSSION AND ANALYSIS	73
13	STATUTORY AUDIT REPORT	110
14	FINANCIAL STATEMENTS FY 2025-26	121

COMPANY INFORMATION

BOARD OF DIRECTORS

Mr. Puneet Dhawan

Mr. Sanchit Hans

Mrs. Tanya Dhawan

Ms. Vandana Gupta

Ms. Laxmi

Managing Director

Whole-Time Director

Non-Executive Director

Independent Woman Director

Independent Woman Director

AUDIT COMMITTEE MEMBERS

Ms. Vandana Gupta

Ms. Laxmi

Mr. Puneet Dhawan

Chairman

Member

Member

CHIEF FINANCIAL OFFICER

Mr. Avtar Singh Rana

COMPANY SECRETARY

Ms. Pooja Garg

STATUTORY AUDITORS

M/s. Shiv & Associates

Chartered Accountants,

Faridabad, Haryana

CORPORATE IDENTITY NUMBER (CIN) L24239DL2019PLC354658

REGISTERED OFFICE

A-16 G T Karnal Road Industrial
Area, Delhi- 110033

BANKERS

State Bank of India.

ICICI Bank Ltd.

HDFC Ltd.

Kotak Mahindra Bank Ltd.


Axis Bank Ltd.

REGISTRAR & SHARE TRANSFER AGENT

Skyline Financial Services Pvt. Ltd.

D-153A, 1st Floor, Okhla Industrial Area,
Phase -I, New Delhi – 110020

Tel. No.: 011-40450193-97 & 011-
26812682- 83



ABOUT THE COMPANY

KRM Ayurveda Limited (formerly known as KRM Ayurveda Private Limited) is an integrated Ayurvedic healthcare and wellness company engaged in providing Ayurveda-based healthcare services, manufacturing and trading of Ayurvedic products, and delivering holistic wellness solutions. The Company was incorporated in September 2019 and subsequently converted into a public company. The name of the Company was changed from KRM Ayurveda Private Limited to KRM Ayurveda Limited with effect from 24 December 2024.

The Company operates at the intersection of traditional Ayurvedic knowledge and contemporary healthcare practices, with a focus on providing holistic, preventive, curative and wellness-oriented healthcare solutions. Its business encompasses Ayurvedic hospitals and clinics, outpatient and inpatient healthcare services, Panchakarma and other Ayurvedic therapies, wellness programmes, diet and lifestyle counselling, yoga and meditation services, telemedicine and Ayurvedic products.

Our Integrated Healthcare Model

KRM Ayurveda has evolved from its initial focus on specialized Ayurvedic healthcare into a broader integrated healthcare platform. The Company's service portfolio includes in-patient and out-patient care, Ayurvedic therapies, Panchakarma, lifestyle management, diet and wellness counselling, yoga and other complementary wellness services.

The Company also leverages tele-consultation and digital healthcare platforms to extend access to Ayurvedic consultation and wellness services beyond its physical healthcare centres. This technology-enabled approach enables the Company to reach patients across different geographies and supports its objective of making Ayurveda more accessible and convenient.

Ayurvedic Products

In addition to healthcare services, KRM Ayurveda is engaged in the manufacturing and trading of Ayurvedic products. Its product portfolio comprises various Ayurvedic formulations and wellness products intended to complement its healthcare and therapeutic offerings.

The Company's product-oriented business enables it to extend its reach beyond its physical healthcare facilities and provides an additional channel for delivering Ayurveda-based wellness solutions to consumers.



Our Approach to Ayurveda

The Company's approach is centred on providing personalized healthcare solutions based on Ayurvedic principles. Its healthcare offerings combine traditional therapeutic practices with structured treatment, dietary guidance, lifestyle management and wellness interventions. The Company's website highlights services including Panchakarma, IPD, OPD, yoga, diet and acupressure, with an emphasis on holistic healing, natural detoxification and mind-body wellness.



Quality and Patient-Centric Care

KRM Ayurveda seeks to build its healthcare platform around quality, authenticity, patient care and trust. The Company states that its healthcare and product offerings are based on Ayurvedic formulations and standards, while its healthcare infrastructure is supported by applicable quality and regulatory frameworks.

The Company also highlights its accreditations and certifications across its operations, including NABH, ISO, FSSAI and AYUSH-related initiatives, as applicable to its respective facilities and activities.



FY 2025-26 — A Transformational Year

FY 2025-26 was an important year in the Company's journey. The Company continued its transition towards an integrated healthcare model, with healthcare services becoming a significantly larger contributor to its overall business mix.

As disclosed by the Company, services contributed approximately 53.77% of total sales in FY2025-26, compared with 9.70% in FY2022-23, reflecting the Company's evolution from a predominantly product-led business towards an integrated healthcare platform.

The Company also strengthened its financial position following its ₹77.49 crore NSE Emerge IPO, providing a stronger capital base to pursue its growth initiatives, including expansion of healthcare infrastructure, telemedicine, medical tourism and product development.



Our Growth STRATEGY

**Going forward, KRM
Ayurveda intends to focus on
the following strategic areas:**

- Expansion of its network of hospitals, clinics and wellness centres;
- Development of specialized Ayurvedic healthcare services;
- Scaling up telemedicine and digital healthcare services;
- Expansion of its Ayurvedic product portfolio and distribution network;
- Strengthening its presence in preventive healthcare and lifestyle management;
- Development of medical tourism and international healthcare opportunities;
- Increasing accessibility of Ayurveda through technology-enabled healthcare solutions; and
- Continuing to integrate traditional Ayurvedic practices with contemporary healthcare delivery models.



Our Vision

KRM Ayurveda seeks to establish itself as a trusted and scalable integrated Ayurvedic healthcare and wellness platform, combining authentic Ayurvedic knowledge, qualified healthcare professionals, technology and patient-centric services.

The Company aims to make Ayurveda more accessible by creating an integrated ecosystem comprising healthcare services, wellness programmes, Ayurvedic products and digital healthcare, while maintaining its focus on quality, patient care and sustainable growth.



CHAIRMAN'S MESSAGE

Dear Shareholders,

It gives me immense pleasure to present the Annual Report of KRM Ayurveda Limited for the financial year 2025–26.

FY 2025–26 has been a significant year for the Company, marked by strong financial performance, continued business transformation and the strengthening of our platform for future growth. We remain committed to building an integrated Ayurvedic healthcare business that combines quality healthcare delivery, technology and the traditional strength of Ayurveda.

Strong Financial Performance

The Company delivered a robust performance during FY 25–26. Revenue from Operations increased to ₹101.69 crore, compared with ₹76.55 crore in the previous year, registering a growth of 32.84% and crossing the important ₹100 crore milestone.

EBITDA increased to ₹31.12 crore from ₹19.14 crore, representing growth of 62.59%, while EBITDA margin improved from approximately 25.00% to 30.60%. PAT increased to ₹20.12 crore from ₹11.21 crore, registering growth of approximately 79.42%. The stronger growth in profitability reflects improving operating leverage, business mix and operational efficiency.

Building an Integrated Healthcare Platform

During FY 25–26, we continued our transformation towards an integrated Ayurvedic healthcare platform, bringing together hospitals, clinics, telemedicine and Ayurvedic medicines within a patient-centric ecosystem.

We believe this integrated model provides multiple avenues for growth while enabling us to build stronger and more enduring relationships with our patients.

Our Growth Strategy

The Company's journey on the NSE Emerge platform represents an important milestone and provides a stronger platform for our next phase of growth. Going forward, disciplined capital allocation will remain a key priority, with focus on healthcare infrastructure, capacity expansion, technology, digital healthcare and strengthening our Ayurvedic product portfolio.



Dr. Puneet Dhawan
Chairman

Our strategy will focus on four key priorities: expanding our hospital and clinic network; accelerating digital and telemedicine capabilities; increasing the domestic and international reach of our Ayurvedic medicines; and strengthening operational excellence, internal controls and corporate governance.

We remain conscious that sustainable growth in healthcare requires unwavering focus on quality, patient experience, regulatory compliance and operational discipline.

Looking Ahead

Our ambition is to build KRM Ayurveda Limited into a leading integrated Ayurvedic healthcare platform, combining the heritage and strength of Ayurveda with modern healthcare delivery and technology.

I would like to express my sincere gratitude to our shareholders, patients, employees, doctors, healthcare professionals, business partners and other stakeholders for their continued trust and support. The dedication of our team has been instrumental in our progress.

As we enter the next phase of our journey, we remain focused on responsible expansion, innovation, operational excellence and creating sustainable long-term value for all our stakeholders.

Thank you for your continued trust and confidence in KRM Ayurveda Limited.


Warm regards,

**Puneet Dhawan
Chairman
KRM Ayurveda Limited**

**Sd/-
Puneet Dhawan
{Chairman}
DIN:08553667**

Journey & Milestones

ROOTED IN AYURVEDA. DRIVEN BY PURPOSE. GROWING WITH TRUST.



From strong beginnings to a nationwide vision –
our journey continues.

Business & Services



1. Physical Hospitals, Clinics & Online Telehealth

- IPD & OPD Care
- Panchakarma & Wellness
- Signature Therapies
- Integrative Wellness
- Supportive Healthcare



2. Products Manufacturing

- GMP & ISO-certified production facility at Kundli, Haryana
- Classical & proprietary Ayurvedic formulations
- Diverse product forms: capsules, tablets, syrups, oil



3. D2C & E-Commerce

- Digital & Direct Distribution
- D2C website with e-commerce capabilities
- YouTube for educational content
- Social media marketing via Google & Meta platforms
- Teleconsultation services with global reach

List of Day Care & Hospitals

S.NO	Name	LOCATION	Day Care/ Hospital	STATE
1	KRM AYURVEDA LTD	BANGALORE	Day Care	KARNATAKA
2	KRM AYURVEDA LTD	PATNA	Day Care	BIHAR
3	KRM AYURVEDA LTD	VAISHALI NAGAR	Hospital	RAJASTHAN
4	KRM AYURVEDA LTD	PRATAP NAGAR	Hospital	RAJASTHAN
5	KRM AYURVEDA LTD	UDAIPUR	Hospital	RAJASTHAN
6	KRM AYURVEDA LTD	AJMER	Day Care	RAJASTHAN
7	KRM AYURVEDA LTD	ANDHERI EAST MUMBAI	Day Care	MAHARASHTRA
8	KRM AYURVEDA LTD	GOMTI NAGAR_Lucknow	Day Care	UTTAR PRADESH
9	KRM AYURVEDA LTD	VIKAS NAGAR_Lucknow	Hospital	UTTAR PRADESH
10	KRM AYURVEDA LTD	NOIDA	Day Care	UTTAR PRADESH
11	AyuKarma Ayurveda	GURUGRAM	Day Care	HARYANA
12	KRM AYURVEDA LTD	KUNDLI	Factory	HARYANA
13	KRM AYURVEDA LTD	A-16 GT KARNAL ROAD	Registered office	DELHI
14	KRM AYURVEDA LTD	PITAMPURA	Hospital	DELHI
15	KRM AYURVEDA LTD	DWARKA	Day Care	DELHI
16	KRM AYURVEDA LTD	JANKAPURI	Day Care	DELHI

Products

**A Wide Product Selection,
Manufactured at a GMP Certified Production Unit**

Our specialized products address KIDNEY & LIVER HEALTH, DIGESTIVE CARE, SKIN WELLNESS, STRESS & LIFESTYLE MANAGEMENT, backed by research, natural herbs, and traditional formulations.

Top 10 Selling Products



**Supra Neph
Tablet**



**KRM Renplus
Ultra Kwath**



**Karma KFT
Tablet**



**Karma T Renal
Plus Tablet**



NEPH TABLET



**Nutriment-K
Capsules**



**Karma CP
Soma Capsule**



Shothnil Tablet



**K-Calm
Tablet**




**Karma K
Shilarz Tablet**

OUR SERVICES

End-to-end healthcare service at
KRM AYURVEDA

At KRM Ayurveda, we provide comprehensive Ayurvedic healthcare services focused on holistic wellness, personalized care, and supportive management of a wide range of health conditions.



KEY DISEASE REVERSALS

- **Kidney failure reversal**
- **Liver detox and reversal**
- **Cancer**
- **Gallbladder**
- **Arthritis**
- **Liver Cirrhosis**

OTHER AREAS OF CARE

- **Thyroid disorders**
- **Cholesterol**
- **Knee Pain**
- **Leucoderma**
- **Alzheimer's disease**
- **Motor Neuron Disease (MND)**
- **Parkinson's disease**
- **Psoriasis**
- **PCOD**
- **Erectile Dysfunction**
- **Eczema**
- **Jaundice**
- **Diabetes**
- **Cerebral Palsy**
- **Panchkarma therapies**

KRM Ayurveda — Comprehensive Ayurvedic Care for Better Health and Well-Being.

OPERATIONAL FINANCIAL HIGHLIGHTS

The Company will continue to focus on strengthening the infrastructure, healthcare team, operational processes and service capabilities of the facility.

Any other material developments, acquisitions, capital expenditure, borrowings, changes in business structure, regulatory developments or significant events occurring during FY 2025-26 should be incorporated in this section based on the Company's actual records.

Financial Highlights

Particulars	<u>FY26</u>	<u>FY25</u>	<u>Ratio</u>
Revenue (in ₹ Crore)	101.69	76.55	33%
EBITDA (in ₹ Crore)	31.12	19.14	63%
EBITDA Margin (in %)	30.6	25	-
PAT (in ₹ Crore)	20.12	11.21	79%
PAT Margin (in %)	19.79	14.65	-
Net Worth (in ₹ Crore)	114.71	23.9	380%



NOTICE OF ANNUAL GENERAL MEETING

Notice is hereby given that the 07th Annual General Meeting of the Members (Shareholders) of KRM Ayurveda Limited, ("the Company") will be held through Video Conferencing (VC)/ Other Audio-Visual Means (OAVM), on Wednesday, the 30th Day of September, 2026 at 12.30 P.M (IST) to transact the following businesses: -

ORDINARY BUSINESS:

1. ADOPTION OF FINANCIAL STATEMENTS

To receive, consider and adopt the Audited Financial Statements (Standalone) for the financial year ended on the 31st March, 2026 together with the reports of the Board of Directors and Auditors thereon.

To consider, review and if thought fit, to pass with or without modification(s), the following resolution as an Ordinary Resolution:

"RESOLVED THAT the Audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2026, together with the Reports of the Board of Directors and Statutory Auditors thereon, as circulated to the Members, be and are hereby considered and adopted."

2. TO RE-APPOINT MR. PUNEET DHAWAN (DIN: 08553667) AS A DIRECTOR WHO RETIRES BY ROTATION AND BEING ELIGIBLE, OFFERS HIMSELF FOR RE-APPOINTMENT, AS A DIRECTOR OF THE COMPANY.

To consider, review and if thought fit, to pass the following resolution as an Ordinary Resolution:

"RESOLVED THAT pursuant to the provision of Section 152 and the Companies (Appointment and qualification of Directors) Rules, 2014 and other applicable provisions (including any modification or re-enactment thereof) if any, of the Companies Act 2013, the approval of shareholders of the Company, be and is hereby accorded for the re-appointment of Mr. Puneet Dhawan (DIN: 08553667) as a "Director", who shall be liable to retire by Rotation being eligible and offered himself for re-appointment."

Brief profile of the Director is enclosed as Annexure – A to this notice.

SPECIAL BUSINESS:

To consider and if thought fit, to pass with or without modification(s), the following resolution as Special Resolution:

3. TO FIX REMUNERATION OF MR. PUNEET DHAWAN, MANAGING DIRECTOR OF THE COMPANY.

"RESOLVED THAT pursuant to the recommendation of Nomination and Remuneration Committee and pursuant to the provision of section 197, 198, 203 and other applicable provisions, if any of the Companies Act, 2013 and Companies (Appointment and remuneration of managerial personnel) Rules, 2014 (including rules notifications, any statutory modification, amendment or re-enactment thereof for the time being in force and as may be enacted from time to time) read with schedule V of the said Act, and such other approval permissions and sanctions of such authorities and/or agencies as may be required in this regard and subject to the provisions of Article of Association of the Company, the approval of the Members be and is hereby accorded for fixation of limit of remuneration of Mr. Puneet Dhawan (DIN: 08553667), Managing Director of the Company with effect from April 1, 2026 to March 31, 2027 as mentioned below:

Basic Salary and Allowances up to 144.00 Lakhs p.a.

RESOLVED FURTHER THAT notwithstanding anything contained in Section 197, 198 and Schedule V of the Companies Act, 2013 or any amendment/re-enactment thereof or any revised/new schedule thereof, in the event of absence of profits or inadequate profits in any financial year, the salary, perquisites and statutory benefits, as set out in the explanatory statement forming part of this resolution be paid as minimum remuneration to Mr. Puneet Dhawan, Managing Director.

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorized to do all such acts, deeds and things, to enter into such agreement(s), deed(s) of amendment(s) or any such document(s), as the Board may, in its absolute discretion, consider necessary, expedient or desirable including power to sub-delegate, in order to give effect to this resolution or as otherwise considered by the Board to be in the best interest of the Company, as it may deem fit."

4. TO APPROVE RELATED PARTY TRANSACTIONS.

To consider and if thought fit, to pass with or without modification(s), the following resolution as

Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Section 188 of the Companies Act, 2013 and Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014 and other applicable provisions and rules thereto, and Regulation 23 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, if applicable and subject to such amendments as may be made therein, the approval of the Members of the Company be and is hereby accorded to the Board of Directors of the Company to enter into transactions as detailed hereunder with following Related Parties as defined under the Act for purchase/sale of goods, services and/or any other business activities during the financial year 2026-27.

Name of Related Party	Maximum Amount of Transaction (Upto)	Type of Transaction
Karma Life Care LLC	250,000,000	Sale of goods or services
Karma Online Services LLC	150,000,000	Sale of goods or services
Karma Management Consultant LLC	50,000,000	Sale of goods or services
Puneet Dhawan	20,000,000	Royalty
Puneet Dhawan	32,500,000	Rent
Som Dev Dhawan	10,000,000	Rent
Tanya Dhawan	1,800,000	Professional Services

5. TO APPROVE APPOINTMENT OF SECRETARIAL AUDITOR

To consider and if thought fit, to pass with or without modification(s), the following resolution as

Ordinary Resolution:

“RESOLVED THAT pursuant to the provisions of Section 204 and other applicable provisions, if any, of the Companies Act, 2013 (“Act”), read with Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, Regulation 24A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), as amended from time to time, and other applicable laws, rules, regulations and guidelines, and based on the recommendation of the Audit Committee and the approval and recommendation of the Board of Directors of the Company, M/s. Amit K Mangla & Company, Company Secretaries in Practice, [FRN: S2020HR736700], a Peer Reviewed Company Secretary/Firm of Company Secretaries, be and is hereby appointed as the Secretarial Auditor of the Company for a term of 1 (one) financial year commencing from Financial Year 2026-27 to conduct the Secretarial Audit of the Company and issue the Secretarial Audit Report in accordance with the applicable provisions of the Act, SEBI LODR Regulations and other applicable laws, at a remuneration of ₹1,00,000/- per annum plus applicable taxes and reimbursement of out-of-pocket expenses, as may be mutually agreed between the Board of Directors and the Secretarial Auditor.

RESOLVED FURTHER THAT the Board of Directors of the Company, including any Committee thereof or any officer authorized by the Board, be and is hereby authorized to determine and finalize the terms and conditions of appointment, remuneration and other incidental matters and to do all such acts, deeds, matters and things as may be necessary, proper, expedient or desirable to give effect to this resolution.”

6. TO APPROVE VARIATION/ADJUSTMENT IN UTILISATION OF IPO PROCEEDS AND AUTHORISATION FOR UTILISATION OF BALANCE IPO PROCEEDS TOWARDS GENERAL CORPORATE PURPOSES

To consider and, if thought fit, to pass the following resolution as a Special Resolution:

“RESOLVED THAT pursuant to the provisions of Section 27 and other applicable provisions, if any, of the Companies Act, 2013, read with the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended from time to time, and other applicable laws, regulations, circulars and guidelines, and subject to such approvals, permissions, consents and sanctions as may be required, the consent of the Members of the Company be and is hereby accorded for the variation/adjustment in the utilization of the Net Proceeds of the Initial Public Offering (“IPO”) of the Company, as set out below:

Particulars	Original Allocation (₹ Crore)	Revised Allocation (₹ Crore)	Variation (₹ Crore)
Issue-related Expenses	11.57	11.77	0.2
Capital Expenditure	13.67	13.67	Nil
CRM Software & Hardware Infrastructure	1.42	1.42	Nil
Human Resources	5.44	5.44	Nil
Repayment / Prepayment of Loan	12.5	12.5	Nil
Working Capital Requirements	22.9	22.9	Nil
General Corporate Purposes	9.99	9.79	(0.20)
Total	77.49	77.49	Nil

RESOLVED FURTHER THAT the amount of ₹0.20 crore reduced from the amount earmarked towards General Corporate Purposes be and is hereby approved to be utilized towards meeting the excess IPO issue-related expenses incurred by the Company, whereby the actual issue-related expenses of ₹11.77 crore are accommodated against the amount originally estimated at ₹11.57 crore.

RESOLVED FURTHER THAT the consent of the Members be and is hereby accorded for utilization, from time to time, of the balance amount of ₹9.79 crore earmarked towards General Corporate Purposes, for such lawful corporate and business purposes as may be permissible under applicable laws and in accordance with the disclosures made in the Prospectus of the Company, including operational and administrative expenses, business development activities, brand building and marketing, strategic business initiatives, capital expenditure, repairs and renovation of business premises, purchase of vehicles for business purposes, working capital requirements and such other purposes as may be permitted under applicable laws.

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorized to determine the timing, amount and manner of utilization of the balance IPO proceeds earmarked towards General Corporate Purposes, subject to applicable statutory and regulatory requirements and the terms and conditions of the Prospectus.

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorized to monitor and ensure utilization of the Net Proceeds in accordance with the Objects of the Issue, the Prospectus, the applicable provisions of the Companies Act, 2013, the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable laws, rules, regulations and guidelines.

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorised to take all such steps, actions and measures and to execute all such documents, applications, undertakings, declarations, letters and writings as may be necessary, expedient or desirable for giving effect to this resolution, including making necessary filings, intimations and disclosures with the Registrar of Companies, Securities and Exchange Board of India, National Stock Exchange of India Limited and/or any other statutory or regulatory authority, as may be applicable."

Regd. Office:

**A-16 G T Karnal Road Industrial Area,
Delhi-110033
CIN: L24239DL2019PLC354658
Email: compliance@krmayurveda.com**

**By and on behalf of the Board of Directors
For KRM Ayurveda Limited**

sd/-
(Puneet Dhawan)
Chairman and Managing Director
(DIN: 08553667)

Date: 03rd September, 2026

Place: New Delhi

NOTES:

- a. a)Ministry of Corporate Affairs ("MCA") vide its General Circular No. 20/2020 dated 5th May 2020 read with the subsequent circulars issued from time to time, the latest one being General Circular No. 03/2025 dated 22nd September, 2025("MCA Circulars") and SEBI vide its Circular No. SEBI/HO/CFD/CFD-PoD2/P/CIR/2024/133 dated October 3, 2024 read with the circulars issued earlier on the subject ("SEBI Circulars"), have permitted to conduct the Annual General Meeting ("AGM") virtually, without physical presence of Members at a common venue.

In compliance with the MCA Circulars and SEBI Circulars, the provisions of the Act and the SEBI Listing Regulations, the 07th Annual General Meeting of the Company is being held virtually.

- b. The relevant Explanatory Statement pursuant to Section 102(1) of the Companies Act, 2013 ("Act") in respect of the special businesses to be transacted under item nos. 3 to 5 of the Notice, is annexed hereto
- c. The relevant information of directors pursuant to Regulation 36(3) of Listing Regulations in respect of Chairman and Managing Director, Whole-Time Director of the Company under item nos. 2 of the Notice, are also annexed.
- d. b)The Notice convening this AGM along with the Integrated Annual Report for financial year ended 31st March, 2026 is being sent by electronic mode to those Members whose e-mail address is registered with the Company/Depositories, unless a Member has specifically requested for a physical copy of the same. Members may kindly note that the Notice convening this AGM and Integrated Annual Report for FY 25-26 will also be available on the Company's website www.krmayurvedaindia.com & website of the Stock Exchanges i.e. National Stock Exchange of India Limited (NSE) at www.nseindia.com respectively and on the website of Central Depository Services (India) Limited (CDSL) at <https://evoting.cdsindia.com>. The Company will also publish an advertisement in the newspapers containing details of the AGM and other relevant information for Members viz. manner of registering e-mail Id., Cut-off date for e-voting, Record Date for payment of dividend, etc.
- e. Since the AGM will be held through VC / OAVM, the Route Map is not annexed in this Notice.
- f. Members attending the meeting through VC/OAVM shall be reckoned for the purpose of quorum under Section 103 of the Act. Members holding equity shares as on Wednesday, September 23, 2026 ("Cut-off date") may join the AGM anytime 30 minutes before the scheduled time by following the procedure outlined in the Notice. A person who is a Member as on the Cut-off date shall be eligible to attend and vote on resolutions proposed at the AGM. Any person who is not a Member as on the Cut-off date shall treat this Notice for informational purpose only.
- g. Attendance through VC/OAVM is restricted and hence, Members shall be eligible to join the meeting on first come-first-serve basis. However, attendance of Members holding more than 2% of the paid-up equity share capital, Institutional investors, Directors, Key Managerial Personnel, and Auditors will not be restricted on first-come-first serve basis.

h. Appointment of Proxy and Attendance Slip:

Since the 07th AGM is being held through VC/OAVM in accordance with the MCA Circulars, physical attendance of Members has been dispensed with. Accordingly, the facility of appointment of proxy would not be available to the Members for attending the 07th AGM, and therefore, proxy form and attendance slip are not annexed to this Notice.

- i. The Company has appointed Mr. Amit Kumar Mangla, Practicing Company Secretary (Membership No. FI1450 and Certificate of Practice No. 22687) as the Scrutinizer for scrutinizing the remote e-voting process as well as voting at the AGM in a fair and transparent manner.
- j. The results declared along with the report of the Scrutinizer shall be placed in the website of the Company www.krmayurvedaIndia.com and on the website of CDSL immediately after the declaration of results by the Chairman or a person authorized by him and the results shall also be communicated to National Stock Exchange of India Limited.
- k. The remote e-voting period commences on 25.09.2026 at 9.00 A.M. and ends on 29.09.2026 at 5.00 P.M. Thereafter, the remote e-voting module shall be disabled for e-voting. E-vote once cast cannot be altered subsequently.
- l. The voting rights of members shall be in proportion to their shares in the paid-up equity share capital of the Company as on cut-off date. A person, whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on cut-off date i.e., 23.09.2026 shall be entitled to vote on the proposed resolutions; and their shareholding on such date shall only be reckoned for the purpose of arriving at the results of the remote e-voting and voting at the AGM. Any person who is not the member of the Company as on the cut-off date should treat this notice for information purpose only.
- m. Corporate shareholders/institutional shareholders intending to send their authorized representative(s) to attend/ vote at the 07th AGM are requested to send from their registered e-mail address, scan copy of the relevant Board Resolution/ Authority Letter, etc. authorizing their representative(s) to attend / vote, to the Scrutinizer on his e-mail ID at csamitkmangla@gmail.com with a copy marked to helpdesk.evoting@cdslindia.com and compliance@krmayurveda.com
- n. Members to intimate change in their details:

Members are requested to intimate changes, if any, pertaining to their name, postal address, e-mail ID, telephone/mobile no., PAN, mandates, choice of nominations, power of attorney, bank details viz., name of the bank and branch details, bank account, MICR code, IFSC code, etc.

For shares held in electronic mode: to their DPs

For shares held in physical mode: to the Company/RTA in prescribed Form ISR-1 and other forms. [SEBI Master Circular No. SEBI/HO/MIRSD/SECFATF/P/CIR/2023/169 dated October 12, 2023]

The facility for making nomination is available for the Members in respect of the shares held by them. Members who have not yet registered their nomination are requested to register the same by submitting Form No. SH-13. [Section 72 of the Act] If a Member desires to opt out or cancel the earlier nomination and record a fresh nomination, he/she may submit the same in Form ISR-3 or SH-14 as the case may be. The said forms can be downloaded from the Company's website www.krmayurvedaIndia.com Members are requested to submit the said details to their DP in case the shares are held by them in dematerialized form and to RTA in case the shares are held in physical form.

o. Dematerialization of shares:

SEBI has mandated the Listed Companies to process service requests# for issue of securities in dematerialized form only, subject to folio being KYC compliant. Accordingly, Members are requested to submit duly filled and signed Form ISR-4. The Form is available on website of Company at www.krmayurvedaIndia.com and RTA at www.skylinerta.com [SEBI Master Circular No. SEBI/ HO/MIRSD/POD-1/P/CIR/2024/37 dated May 7, 2024] # Request for issue of duplicate securities certificate; claim from unclaimed suspense account; renewal/exchange of securities certificate; endorsement; sub-division/splitting of securities certificate; consolidation of securities certificates/ folios; transmission and transposition.

Transfer, transmission and transposition of securities shall be effected only in dematerialized form. In view of the same and to eliminate all risks associated with physical shares and avail various benefits of dematerialization, Members are advised to dematerialize the shares held by them in physical form. Members can contact the Company/RTA for assistance in this regard. [Regulation 40(1) of the SEBI Listing Regulations]

- p. Members who have not registered their e-mail IDs are requested to register/update the same with their Depository Participants to promote the green initiative and thus, help preserve the environment. Any person, who acquires shares of the Company and becomes a member of the Company after dispatch of the Notice and holding shares as on cut-off date, may cast vote as provided in the Notice convening the Meeting, which is available on the website of the Company.
- q. Members holding more than one physical folios in identical order of names are requested to submit Form ISR-4 along with requisite KYC documents and share certificates to the Company/RTA for consolidation of holdings in one folio. The consolidated share certificate will be issued in dematerialized form only.
- r. Members seeking clarifications on the Annual Report are requested to send in writing through email: compliance@krmayurveda.com at least 7 days before the date of meeting. This would enable the company to compile the information and give replies to all the clarifications sought by the members, in the meeting.
- s. The Register of Directors and Key Managerial Personnel and their shareholding maintained under Section 170 of the Act and the Register of Contracts or Arrangements in which Directors are interested maintained under Section 189 of the Act, and all the documents referred to in the accompanying Notice, are open for inspection in electronic form by the members during the AGM. All documents referred to in the Notice will also be available for inspection by the members at the registered office of the Company during office hours on all working days between 11.00 a.m. and 4.00 p.m. on all days except Saturdays, Sundays and public holidays, from the date hereof up to the date of the Meeting and at the venue of the Meeting for the duration of the Meeting. Members seeking to inspect such documents can send an email to compliance@krmayurveda.com.

THE INTRUCTIONS OF SHAREHOLDERS FOR E-VOTING AND JOINING VIRTUAL MEETINGS ARE AS UNDER:

Step 1 : Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.

Step 2 : Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.

(i) The voting period begins on **25th September, 2026 at 9:00 a.m. and ends on 29th September, 2026 at 5:00 p.m.** During this period shareholders of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date (record date) of 23rd September, 2026 may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.

(ii) Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.

(iii) Pursuant to **SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 09.12.2020**, under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level.

Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.

In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to all the demat account holders, by way of a single login credential, through their demat accounts/ websites of Depositories/ Depository Participants. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

Step 1 : Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.

(iv) In terms of **SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 9, 2020** on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Pursuant to abovesaid SEBI Circular, Login method for e-Voting and joining virtual meetings **for Individual shareholders holding securities in Demat mode CDSL/NSDL is given below:**

Type of shareholders	Login Method
Individual Shareholders holding securities in Demat mode with CDSL Depository	1) Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login to Easi / Easiest are requested to visit cdsi website www.cdslindia.com and click on login icon & My Easi New (Token) Tab. 2) After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly. 3) If the user is not registered for Easi/Easiest, option to register is available at cdsi website www.cdslindia.com and click on login & My Easi New (Token) Tab and then click on registration option. 4) Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.

Individual Shareholders holding securities in demat mode with **NSDL Depository**

1) If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: <https://eservices.nsdl.com> either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the “Beneficial Owner” icon under “Login” which is available under ‘IDeAS’ section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on “Access to e-Voting” under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

2) If the user is not registered for IDeAS e-Services, option to register is available at <https://eservices.nsdl.com>. Select “Register Online for IDeAS” “Portal” or click at <https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp>

3) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting

4) For OTP based login you can click on <https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp>. You will have to enter your 8-digit DP ID, 8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Individual Shareholders (holding securities in demat mode) login through their Depository Participants (DP)	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.
--	---

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login type	Helpdesk details
Individual Shareholders holding securities in Demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 21 09911
Individual Shareholders holding securities in Demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.com or call at: 022 - 4886 7000 and 022 - 2499 7000

Step 2 : Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.

(v) Login method for e-Voting and joining virtual meetings for Physical shareholders and shareholders other than individual holding in Demat form.

1. The shareholders should log on to the e-voting website www.evotingindia.com.
2. Click on "Shareholders" module.
3. Now enter your User ID
 - a.For CDSL: 16 digits beneficiary ID,
 - b.For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
 - c.Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.
4. Next enter the Image Verification as displayed and Click on Login.
5. If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier e-voting of any company, then your existing password is to be used.
6. If you are a first-time user follow the steps given below:

For Physical shareholders and other than individual shareholders holding shares in Demat.

PAN	Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) • Shareholders who have not updated their PAN with the Company/ Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.
Dividend Bank Details OR Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login. • If both the details are not recorded with the depository or company, please enter the member id / folio number in the Dividend Bank details field.

- (vi) After entering these details appropriately, click on "SUBMIT" tab.
- (vii) Shareholders holding shares in physical form will then directly reach the Company selection screen. However, shareholders holding shares in demat form will now reach 'Password Creation' menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- (viii) For shareholders holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- (ix) Click on the EVSN for the relevant <KRM AYURVEDA LIMITED> on which you choose to vote.
- (x) On the voting page, you will see "RESOLUTION DESCRIPTION" and against the same the option "YES/NO" for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- (xi) Click on the "RESOLUTIONS FILE LINK" if you wish to view the entire Resolution details.
- (xii) After selecting the resolution, you have decided to vote on, click on "SUBMIT". A confirmation box will be displayed. If you wish to confirm your vote, click on "OK", else to change your vote, click on "CANCEL" and accordingly modify your vote.

- (xiii) Once you “CONFIRM” your vote on the resolution, you will not be allowed to modify your vote.
- (xiv) You can also take a print of the votes cast by clicking on “Click here to print” option on the Voting page.
- (xv) If a demat account holder has forgotten the login password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
- (xvi) There is also an optional provision to upload BR/POA if any uploaded, which will be made available to scrutinizer for verification.
- (xvii) **Additional Facility for Non – Individual Shareholders and Custodians –For Remote Voting only.**
- Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to www.evotingindia.com and register themselves in the “Corporates” module.
 - A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
 - After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
 - The list of accounts linked in the login will be mapped automatically & can be delink in case of any wrong mapping.
 - It is Mandatory that, a scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
 - Alternatively non-individual shareholders are required mandatory to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address viz; csamitkmangla@gmail.com (designated email address by company), if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

INSTRUCTIONS FOR SHAREHOLDERS ATTENDING THE AGM/EGM THROUGH VC/OAVM & E-VOTING DURING MEETING ARE AS UNDER:

1. The procedure for attending meeting & e-Voting on the day of the AGM/ EGM is same as the instructions mentioned above for e-voting.
2. The link for VC/OAVM to attend meeting will be available where the EVSN of Company will be displayed after successful login as per the instructions mentioned above for e-voting.
3. Shareholders who have voted through Remote e-Voting will be eligible to attend the meeting. However, they will not be eligible to vote at the AGM/EGM.
4. Shareholders are encouraged to join the Meeting through Laptops / IPads for better experience.
5. Further shareholders will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
6. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
7. Shareholders who would like to express their views/ask questions during the meeting may register themselves as a speaker by sending their request in advance atleast 7 days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at (company email id). The shareholders who do not wish to speak during the AGM but have queries may send their queries in advance 7 days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at (company email id). These queries will be replied to by the company suitably by email.
8. Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.
9. Only those shareholders, who are present in the AGM/EGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system available during the EGM/AGM.
10. If any Votes are cast by the shareholders through the e-voting available during the EGM/AGM and if the same shareholders have not participated in the meeting through VC/OAVM facility, then the votes cast by such shareholders may be considered invalid as the facility of e-voting during the meeting is available only to the shareholders attending the meeting.

PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL/MOBILE NO. ARE NOT REGISTERED WITH THE COMPANY/DEPOSITORIES.

1. For Physical shareholders- please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to Company/RTA email id.
2. For Demat shareholders -, Please update your email id & mobile no. with your respective Depository Participant (DP)

3. For Individual Demat shareholders – Please update your email id & mobile no. with your respective Depository Participant (DP) which is mandatory while e-Voting & joining virtual meetings through Depository.

If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting System, you can write an email to helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 21 09911

All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, AVP, (CDSL) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai – 400013 or send an email to helpdesk.evoting@cdslindia.com or call toll free no. 1800 21 09911.

ANNEXURE TO THE ITEM NO. 2

Pursuant to Regulation 36(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

DETAILS OF CHAIRMAN AND WHOLE TIME DIRECTOR (WTD), MANAGING DIRECTOR (MD) AND CEO and NON- EXECUTIVE AND INDEPENDENT DIRECTORS SEEKING APPOINTMENT/RE- APPOINTMENT/RE- DESIGNATION AT THE FORTHCOMING ANNUAL GENERAL MEETING

Name of the Director/s (DIN)	Mr. Puneet Dhawan, Chairman & MD (DIN: 08553667)
Ref. of item no. of Notice dated the 03rd September, 2026	2
Date of Birth	10.12.1987
Age of Directors	38 Years
Date of First Appointment on the Board	03.09.2019
Qualifications	BAMS
Expertise in specific functional areas / Experience and brief resume	Mr. Puneet Dhawan is the Managing Director of KRM Ayurveda Limited and a fifth-generation Ayurvedic practitioner, carrying forward a distinguished legacy of Ayurveda. A B.A.M.S. graduate from Delhi University, he brings a strong combination of clinical knowledge, entrepreneurial vision and strategic leadership to the organisation. Under his leadership, KRM Ayurveda is building an integrated healthcare platform spanning Ayurvedic hospitals, clinics, telemedicine, pharmaceutical and herbal products, and international markets. His vision is centred on blending the heritage of Ayurveda with modern healthcare infrastructure, technology and global best practices, with the objective of making authentic, personalised Ayurveda accessible to patients across India and international markets.
Name of other listed companies in which Directorships held by such persons	NIL
Name of listed entities from which the said director has resigned in the past three years	NIL

Name of other listed companies in which such persons holding Membership of committee of the Board	NIL
Remuneration last drawn	84.00 lakhs p.a.
Remuneration proposed to be drawn	144.00 lakhs p.a.
No. of meeting of the Board attended during the FY 2025-26	Mentioned in Directors Report
Shareholding in the Company	1,42,20,400
Relationship between directors inter-se	Not Related

EXPLANATORY STATEMENTS PURSUANT TO SECTION 102(1) OF THE COMPANIES ACT, 2013

ITEM NO. 3

The members of the company have appointed Mr. Puneet Dhawan as Managing Director in Extra-Ordinary General Meeting held on 15th March, 2025. It is proposed to fix their remuneration for financial year 2026-2027 for a period of one year.

The particulars of the proposed remuneration are as follows:

Name of Related Party	Mr. Puneet Dhawan
Designation	Managing Director
Terms of Remuneration	One (1) year
Monthly gross salary	12,00,000/- p.m.
Annual Remuneration	₹1,44,00,000/-

Based on the net profits of the Company calculated in accordance with the provisions of Section 198 of the Companies Act, 2013 ("the Act"), the proposed remuneration payable to Mr. Puneet Dhawan, Managing Director, is within the overall managerial remuneration limit of eleven per cent of the net profits of the Company prescribed under Section 197(1) of the Act.

However, the proposed remuneration payable to Mr. Puneet Dhawan exceeds the limit of five per cent of the net profits of the Company prescribed under Section 197(1)(i) of the Act in respect of remuneration payable to any one Managing Director/Whole-time Director/Manager. Accordingly, approval of the members by way of a Special Resolution is being sought for payment of the proposed remuneration to Mr. Puneet Dhawan for the financial year 2026-2027, in accordance with the applicable provisions of the Act.

It is hereby confirmed that the Company has not committed any default in payment of dues to any bank or public financial institution or any other secured creditor.

Mr. Puneet Dhawan, being the Managing Director, whose remuneration is proposed to be approved, is concerned or interested in the proposed Special Resolution. None of the other Directors or Key Managerial Personnel of the Company, or their respective relatives, is, in any way, concerned or interested, financially or otherwise, in the proposed Special Resolution, except to the extent of their shareholding, if any, in the Company.

The Board of Directors accordingly recommends the resolution for your approval.

ITEM NO. 4

In accordance with the provisions of Section 188 of the Companies Act, 2013 ("the Act") read with Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014 and Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, approval of the shareholders is required for entering into material related party transactions (RPT) as mentioned above in the notice of the Annual General Meeting.

The Audit Committee and the Board of Directors of the Company, at their respective meetings held on 03rd September, 2026, have approved the proposed related party transactions (RPT) and recommended the same for the approval of the shareholders.

Information pursuant to SEBI Circular SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated November 22, 2021& under Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014 are as follows:

1	Name of Related Parties	Karma Life Care LLC	Karma Online Services LLC	Karma Management Consultant LLC	Mr. Puneet Dhawan	Mr. Puneet Dhawan	Mr. Som Dev Dhawan	Ms. Tanya Dhawan
2	Nature of Relationship	Entities in which KMPs have significant influence	Entities in which KMPs have significant influence	Entities in which KMPs have significant influence	Director/Managing Director and Related Party	Director/Managing Director and Related Party	Relative of Director	Director
3	Value of Transaction	₹25.00 Crore (approx.)	₹15.00 Crore (approx.)	₹5.00 Crore (approx.)	₹2.00 Crore (approx.)	₹3.25 Crore (approx.)	₹1.00 Crore (approx.)	₹0.18 Crore (approx.)
4	Nature of Transaction/ Contract	Sale of goods/s services	Sale of goods/s services	Sale of goods/s services	Royalty	Rent	Rent	Consultancy Fees
5	Tenure/ duration of the transaction	Ongoing Transactions (year on year)	Ongoing Transactions (year on year)	Ongoing Transactions (year on year)	Transactions for FY 2026-2027 to 2028-29. (3 year)	Transactions for FY 2026-27. (1 year)	Transactions for FY 2026-27. (1 year)	Ongoing Transactions (year on year)

6	If the transaction relates to any loans, inter-corporate deposits, advances or investments made or given by the listed entity or its subsidiary, Applicable terms, including covenants, tenure, interest rate and repayment schedule, whether secured or unsecured, if secured, the nature of security	NA	NA	NA	NA	NA	NA	NA
7	Any other information relevant or important for the Board to take a decision on the proposed transaction.							

8	Justification as to why the related party transaction is in the interest of the listed entity	The proposed transactions are in the ordinary course of business of the Company and are undertaken to facilitate the sale and supply of the Company's products/services in the relevant market. In FY25-26 entity has achieved a turnover of 16.93 crore and will expect it to grow upto 25 crore in FY26-27. The transactions provide the Company with an established business channel and support revenue generation and business expansion. The transactions are considered to be in the interest of the Company as they are expected to contribute to its operating revenue and business growth.	The proposed transactions are in the ordinary course of business of the Company and are undertaken to facilitate the sale and supply of the Company's products/services in the relevant market. In FY25-26 entity has achieved a turnover of 9.1 crore and will expect it to grow upto 15 crore in FY26-27. The transactions provide the Company with an established business channel and support revenue generation and business expansion. The transactions are considered to be in the interest of the Company as they are expected to contribute to its operating revenue and business growth.	The proposed transactions are in the ordinary course of business of the Company and are undertaken to facilitate the sale and supply of the Company's products/services in the relevant market. In FY26-27 company expect to grow a business with this entity in strategic market and expect a turnover around 5 crore. The transactions provide the Company with an established business channel and support revenue generation and business expansion. The transactions are considered to be in the interest of the Company as they are expected to contribute to its operating revenue and business growth.	The royalty payment is proposed in consideration of the use of intellectual property, know-how, brand, technical/business expertise and/or other rights and resources made available to the Company, as applicable under the underlying arrangement.	The rent is proposed towards use of premises/assets made available to the Company for its business operations. The arrangement enables the Company to use the required premises/assets without incurring the capital costs and administrative burden associated with acquiring or arranging alternative premises/assets to align with the Asset Light strategy of the Company. The transaction is therefore considered to be in the ordinary course of business and in the interest of the Company.	The rent is proposed towards use of premises/assets made available to the Company for its business operations. The arrangement enables the Company to use the required premises/assets without incurring the capital costs and administrative burden associated with acquiring or arranging alternative premises/assets to align with the Asset Light strategy of the Company. The transaction is therefore considered to be in the ordinary course of business and in the interest of the Company.	The consultancy fees are proposed towards professional/consultancy services provided to the Company in connection with its business and operational requirements. The services are expected to provide the Company with relevant expertise and support its business activities.
---	---	---	---	---	---	--	--	--

9	The manner of determining the pricing and other commercial terms, both included as part of Contract and not considered as part of contract	The pricing and other commercial terms are determined based on the prevailing market conditions, nature and volume of goods/services, cost of goods/services, applicable taxes, logistics and other relevant commercial considerations.	The pricing is determined based on the prevailing market rates, nature and volume of goods/services, cost structure, applicable taxes, logistics and other commercial factors.	The pricing and commercial terms are determined considering the nature and volume of goods/services, prevailing market conditions, cost of supply/provision, applicable taxes, logistics and other relevant commercial factors.	The royalty payable under the agreement has been determined based on the nature and extent of rights, intellectual property, brand value, know-how, expertise and other benefits made available to the Company.	The rent payable under the agreement has been determined based on the location, area, nature and condition of the premises, prevailing market rental rates for comparable premises, tenure of the arrangement and other relevant commercial considerations.	The rent payable under the agreement has been determined based on the location, area, nature and condition of the premises, prevailing market rental rates for comparable premises, tenure of the arrangement and other relevant commercial considerations.	The consultancy fees payable under the agreement have been determined considering the nature and scope of services, expertise and experience required, time and resources involved, duration of the engagement, prevailing market rates for comparable consultancy services and the expected benefits to the Company.
10	% of the listed entity annual turnover for the immediately preceding financial year, that is represented by the value of the proposed transaction	24.58%	14.75%	4.92%	1.97%	3.20%	0.98%	0.18%

11	Percentage of the counter-party's annual consolidated turnover that is represented by the value of the proposed RPT on a voluntary basis	147.70%	164.75%	NA	NA	NA	NA	55.37%
----	--	---------	---------	----	----	----	----	--------

These transactions are necessary for the smooth conduct of the business and are in the best interest of the Company. None of the Directors, Key Managerial Personnel (KMP) or their relatives, except to the extent of their interest in the respective related parties, are concerned or interested, financially or otherwise, in the said resolution.

The Board recommends the resolution no 04 as set out in the accompanying Notice for approval of the members by way of an Ordinary Resolution.

ITEM NO. 5

The Securities and Exchange Board of India ("SEBI") vide the SEBI (Listing Obligations and Disclosure Requirements) (Third Amendment) Regulations, 2024 amended Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations") in relation to appointment, re-appointment and continuation of Secretarial Auditors of listed entities.

Pursuant to the amended Regulation 24A of the SEBI LODR Regulations, every listed entity is required to undertake Secretarial Audit through a Secretarial Auditor who is a Peer Reviewed Company Secretary. Further, based on the recommendation of the Board of Directors, a listed entity is required to appoint or re-appoint an individual Secretarial Auditor for not more than one term of five consecutive years or a Secretarial Audit firm for not more than two terms of five consecutive years, with the approval of the shareholders at the Annual General Meeting.

Accordingly, based on the recommendation of the Audit Committee, the Board of Directors of the Company at its meeting held on September 03, 2026, considered and approved the appointment of M/s. Amit K Mangla & Company, Company Secretaries in Practice, [FRN: S2020HR736700] as the Secretarial Auditor of the Company for a term of 1 (One) consecutive financial years commencing from Financial Year 2026-27, subject to the approval of the members of the Company at the ensuing Annual General Meeting.

The proposed Secretarial Auditor is a Peer Reviewed Company Secretary/Firm and is eligible for appointment in accordance with the applicable provisions of the Companies Act, 2013 and Regulation 24A of the SEBI LODR Regulations.

The proposed Secretarial Auditor has provided its consent to act as the Secretarial Auditor of the Company and has confirmed that the proposed appointment, if approved by the members, shall be in accordance with the applicable provisions of the Companies Act, 2013, the rules made thereunder and Regulation 24A of the SEBI LODR Regulations, including the eligibility, qualification and other applicable requirements.

The proposed Secretarial Auditor has also confirmed that it has not incurred any of the disqualifications prescribed under the applicable provisions and that it satisfies the eligibility criteria prescribed under Regulation 24A of the SEBI LODR Regulations.

The Board, after considering the qualifications, experience, expertise, professional competence and suitability of the proposed Secretarial Auditor, is of the opinion that the appointment of M/s. Amit K Mangla & Company, would be in the best interests of the Company and recommends the resolution set out at Item No. 5 for approval of the members by way of an Ordinary Resolution.

The proposed remuneration payable to the Secretarial Auditor shall be ₹1,00,000/- per annum plus applicable taxes and reimbursement of out-of-pocket expenses, as may be mutually agreed between the Board of Directors and the Secretarial Auditor.

The Secretarial Auditor may also be engaged for such other permissible professional services as may be approved by the Board of Directors based on the recommendation of the Audit Committee, subject to the applicable provisions of Regulation 24A of the SEBI LODR Regulations.

None of the Directors, Key Managerial Personnel of the Company or their respective relatives is concerned or interested, financially or otherwise, in the resolution set out at Item No. 5 of the Notice.

The Board of Directors recommends the Ordinary Resolution set out at Item No. 5 for approval of the members.

ITEM NO. 6

The Company had undertaken an Initial Public Offering ("IPO") and the Net Proceeds thereof were proposed to be utilized towards the Objects of the Issue as disclosed in the Prospectus of the Company.

The Board of Directors, at its meeting held on 01st May 2026, reviewed the utilization of the IPO proceeds for the quarter ended 31st March 2026. The Company incurred issue-related expenses of ₹11.77 crore as against the estimated amount of ₹11.57 crore, resulting in an excess expenditure of ₹0.20 crore.

Accordingly, the Company proposes to adjust ₹0.20 crore from the amount earmarked towards General Corporate Purposes ("GCP") towards the aforesaid excess issue-related expenses. Consequently, the amount earmarked for GCP will be reduced from ₹9.99 crore to ₹9.79 crore. There is no change proposed in the other Objects of the Issue.

The balance amount of ₹9.79 crore earmarked towards GCP shall be utilized from time to time for lawful corporate and business purposes, in accordance with the disclosures made in the Prospectus and applicable laws.

The proposed variation is intended to accommodate the actual issue-related expenses incurred by the Company and does not involve any increase in the overall IPO proceeds raised by the Company.

The Board recommends the Special Resolution set out at Item No. 6 for approval by the Members.

None of the Directors, Key Managerial Personnel of the Company and their respective relatives is concerned or interested, financially or otherwise, in the proposed resolution, except to the extent of their respective shareholding, if any, in the Company.

ATTENDANCE SLIP

TO BE HANDED OVER AT THE ENTRANCE OF THE MEETING VENUE

LEDGER FOLIO No	
DP ID No.*	
Client ID No.*	

* Applicable to members holding shares in electronic form

Member/Proxy Holder Name	Father's / Husband's Name	Signature (s)

I hereby record my presence at the **07th Annual General Meeting** of the Company held on **Wednesday, 30th Day of September, 2026 at 12.30 P.M.** at registered office of the Company at A-16 G T Karnal Road Industrial Area, Delhi-110033

Signature of the Member / Proxy

(To be signed at the time of handing over this slip)

NOTE: SHARE HOLDERS/ PROXY HOLDERS DESIRING TO ATTEND THE MEETING SHOULD BRING HIS/HER COPY OF ANNUAL REPORT FOR REFERENCE AT THE MEETING

Proxy Form

[Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies (Management and Administration) Rules, 2014]

CIN:	L24239DL2019PLC354658
Name of the company:	KRM AYURVEDA LIMITED
Registered office:	A-16 G T KARNAL ROAD INDUSTRIAL AREA, North West, DELHI-110033
Venue of the Meeting:	A-16 G T KARNAL ROAD INDUSTRIAL AREA, North West, DELHI-110033
Name of the member (s):	
Registered address:	
E-mail Id:	
Folio No/ Client Id:	
DP ID:	
I/We, being the member (s) of shares of the above-named company, hereby appoint	
1. Name	
Address	
E-mail Id	
Signature :..... , or failing him	

2. Name	
Address	
E-mail Id	
Signature :..... , or failing him	
3. Name	
Address	
E-mail Id	
Signature :.....	

as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the **07TH Annual General Meeting** of the Company, to be held on **Wednesday, 30th day of September, 2026 at 12.30 P.M.** at registered office of the Company at **A-16 G T Karnal Road Industrial Area, Delhi-110033** and at any adjournment thereof in respect of such resolutions as are indicated below:

Resolution No.	Details of Resolution	For	Against
1	To receive, consider and adopt the audited financial statement of the Company for the financial year ended 31st March 2026 together with the reports of the Board of Directors and the Auditors thereon.		
2	To re-appoint Mr. Puneet Dhawan (DIN: 08553667) as a director who retires by rotation and being eligible, offers himself for re-appointment, as a Director of the Company.		
3	To fix remuneration of Mr. Puneet Dhawan, Managing Director of the Company.		
4	To approve related party transactions.		
5	To approve appointment of Secretarial Auditor.		
6	To approve variation/adjustment in utilisation of IPO proceeds and authorisation for utilisation of balance IPO proceeds towards General Corporate Purposes		

Signed this..... day of..... 2026

Signature of Shareholder: _____

Signature of Proxy holder(s): _____

**Affix Re. 1
Revenue Stamp**

Notes:

- (1) This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company not less than 48 hours before the commencement of the meeting.
- (2) A Proxy need not be a member of the Company.
- (3) A person can act as a proxy on behalf of members not exceeding fifty and holding in the aggregate not more than 10% of the total share capital of the Company carrying voting rights. A member holding more than 10% of the total share capital of the Company carrying voting rights may appoint a single person as proxy and such person shall not act as a proxy for any other person or shareholder.
- ** (4) This is only optional. Please put a 'ü' in the appropriate column against the resolutions indicated in the Box. If you leave the 'For' or 'Against' column blank against any or all the resolutions, your Proxy will be entitled to vote in the manner as he/she thinks appropriate.
- (5) Appointing a proxy does not prevent a member from attending the meeting in person if he so wishes.
- (6) In the case of joint holders, the signature of any one holder will be sufficient, but names of all the joint holders should be stated.

DECLARATION RELATING TO COMPLIANCE WITH THE CODE OF CONDUCT FOR BOARD MEMBERS AND SENIOR MANAGEMENT PERSONNEL

This is to certify that the Company has laid down a Code of Conduct (the Code) for all Board Members and Senior Management Personnel of the Company and a copy of the Code is put on the website of the Company www.krmayurvedaindia.com

I, Puneet Dhawan, Managing Director of the Company, hereby confirm that all the members of the Board and the Senior Management Personnel of the Company, have confirmed the compliance to the Code of Conduct of the Company, during the year ended March 31, 2026.

On behalf of Board of Directors

**For KRM Ayurveda Limited
(Formerly known as KRM Ayurveda Private Limited)**

**Sd/-
Puneet Dhawan
Managing Director
DIN: 08553667**

**Place: - New Delhi
Date: - 03.09.2026**

CHIEF FINANCIAL OFFICER CERTIFICATION UNDER REGULATION 17(8) OF SEBI (LODR) REGULATIONS

To
The Board of Directors
KRM Ayurveda Limited
(Formerly known as KRM Ayurveda Private Limited)

I, Avtar Singh Rana, Chief Financial Officer of KRM Ayurveda Limited (Formerly known as KRM Ayurveda Private Limited), hereby certify that:

a) I have reviewed financial statements and the cash flow statement for the year ended March 31, 2026 and that to the best of my knowledge and belief here state that:

i) these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;

ii) these statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.

b) There are, to the best of my knowledge and belief, no transactions entered into by the Company during the year that are fraudulent, illegal, or violative of the Company's code of conduct.

c) I accept responsibility for establishing and maintaining internal controls for financial reporting and that I have evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting and have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of such internal controls, if any, of which I am aware and the steps taken or proposed to be taken to rectify these deficiencies.

d) I have indicated to the auditors and the Audit Committee that there were:

i) no significant changes in internal control over financial reporting during the year

ii) no significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and

iii) no instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an employee having a significant role in the Company's internal control system over financial reporting

For KRM Ayurveda Limited
(Formerly known as KRM Ayurveda Private Limited)

Sd/-
Avtar Singh Rana
Chief Financial Officer

Date: 03.09.2026
Place: New Delhi

DIRECTORS' REPORT

Dear Members/ Shareholders,

Your directors are pleased to present the 07th Annual Report together with the Audited Standalone Financial Statements of the Company for the Financial year ended on the 31st March, 2026.

COMPANY PERFORMANCE

Financial Highlights

The financial performance of the Company for the financial year ended 31 March 2026, as compared with the previous financial year, is summarized below:

(Rs in Lakhs)

Particulars	Year ended March, 2026	Year ended March, 2025
Revenue from Operations	10,169.07	7,655.27
Other Income	62.33	39.7
Total Income	10,231.40	7,694.97
Expenses	7,558.83	6,175.19
Profit/(Loss) Before Tax	2,672.57	1,519.78
Tax Expense	660.57	398.37
Profit/(Loss) After Tax	2,012.00	1,121.41

FINANCIAL PERFORMANCE AND BUSINESS REVIEW:

Net Profit for the Financial year 2025-26 stood at Rs. 2,012.00 lakhs as against profit of Rs. 1,121.41 lakhs in the Financial Year 2024-25. The total income including turnover for the Financial Year 2025-26 stood at Rs. 10,231.40 lakhs, as compared to Rs. 7,694.97 lakhs for the Financial Year 2024-25.

The Board is continuously working for the better performance of the Company in the years to come. The company will continue to pursue expansion in the domestic and international market, to achieve sustained and profitable growth.

Any member intending to have a copy of Balance Sheet and other Financial Statement of these Companies shall be made available on the website of the Company at <https://www.krmayurvedaindia.com/>

CAPITAL STRUCTURE

During the financial year 2025-26, there were changes in the authorized and paid-up share capital of the Company.

The details of the changes are as follows:

1. Increase in Authorized Share Capital-

The Authorised Share Capital of the Company was increased from ₹20,00,000/- (Rupees Twenty Lakhs only) comprising 2,00,000 Equity Shares of ₹10/- each to ₹25,00,00,000/- (Rupees Twenty-Five Crores only) comprising 2,50,00,000 Equity Shares of ₹10/- each, ranking pari passu in all respects with the existing Equity Shares of the Company.

2. Issue of Bonus Shares

During the year under review, the Company issued 1,48,50,000 fully paid-up Equity Shares as Bonus Shares to the shareholders of the Company on 17 July 2025, in accordance with the applicable provisions of the Companies Act, 2013 and the resolutions passed by the shareholders.

3. Issue of Equity Shares through Private Placement

The Company further allotted 5,20,800 Equity Shares through private placement to the proposed allottees on 21 August 2025, subject to applicable provisions of the Companies Act, 2013 and the rules made thereunder.

4. Issue of Equity Shares through Initial Public Offering

During the year under review, the Company allotted 57,40,000 (Fifty-Seven Lakhs Forty Thousand) Equity Shares of ₹10/- each pursuant to the Initial Public Offering (IPO) of the Company on 27 January 2026, in accordance with the

applicable provisions of the Companies Act, 2013, the rules made thereunder and other applicable regulatory requirements.

5. Paid-Up Share Capital

Consequent upon the aforesaid changes in the share capital of the Company, the paid-up equity share capital of the Company as on 31 March 2026 stood at ₹21,26,08,000/- (Rupees Twenty-One Crores Twenty-Six Lakhs Eight Thousand only), comprising 2,12,60,800 Equity Shares of ₹10/- each.

LISTING OF EQUITY SHARES

During the financial year under review, the equity shares of the Company were listed on the NSE Emerge Platform of the National Stock Exchange of India Limited ("NSE") with effect from 29 January 2026.

The Company has complied with the applicable listing requirements and has paid the applicable annual listing fees to NSE for the relevant period.

DEMATRIALIZATION OF EQUITY SHARES

All the Equity Shares of the Company are held in dematerialized form with the depositories, namely National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL).

The ISIN allotted to the Company Equity Shares is INE1MTV01019.

DIVIDEND

With a view to conserve resources for the Company's future requirements, business expansion and strengthening of its financial position, the Board of Directors has decided to retain the profits of the Company.

Accordingly, the Board of Directors does not recommend any dividend for the financial year ended 31 March 2026.



TRANSFER TO INVESTOR EDUCATION AND PROTECTION FUND

During the financial year under review, there was no amount of dividend remaining unpaid or unclaimed for the period prescribed under Section 124 of the Companies Act, 2013, and accordingly, no amount was required to be transferred to the Investor Education and Protection Fund ("IEPF").

Further, no shares were required to be transferred to the IEPF during the year under review.

TRANSFER TO RESERVES

During the Financial Year under review, the Company has transferred an amount of Rs. 527.00 Lakhs to the Reserves & Surplus.

MANAGEMENT DISCUSSION AND ANALYSIS

A detailed review of operations, performance and future outlook of your Company and its businesses is given in the Management's Discussion and Analysis Report, which forms part of the report is annexed to this Report as Annexure- A.

SUBSIDIARIES, ASSOCIATE AND JOINT VENTURES

The Company does not have any subsidiary, associate or joint venture company as on March 31, 2026.

Accordingly, the provisions relating to preparation of consolidated financial statements and disclosures concerning subsidiaries, associates and joint ventures, to the extent applicable, do not arise.

CHANGE IN THE NATURE OF BUSINESS, IF ANY

During the year under review, there was no change in the nature of the Company's business. The Company continued to operate in its existing line of business. The foray into hospitals complements the Company's existing business operations and is expected



to create operational synergies, enhance value for stakeholders, and support sustainable long-term growth.

DEPOSITS

During the year under review, the Company has not accepted or renewed any deposit from the public falling within the ambit of section 73 of the Companies Act, 2013 and the Companies (Acceptance and Deposits) Rules, 2014.

Accordingly, the provisions relating to acceptance of deposits from the public were not applicable to the Company during the year under review.

EXTRACT OF ANNUAL RETURN

Pursuant to Section 92 of the Companies Act, 2013, the Annual Return of the Company as on 31 March 2026 shall be made available on the website of the Company at the applicable statutory/investor information section at https://www.krmayurvedaindia.com/documents/Form_MGT-7_2025-26.pdf

CORPORATE GOVERNANCE

The equity shares of the Company were listed on the NSE EMERGE Platform of the National Stock Exchange of India Limited on January 29, 2026.

Since the Company is listed on the SME Exchange/Platform, the exemption available under Regulation 15(2) of the SEBI Listing Regulations in respect of specified corporate governance provisions has been considered. Regulation 15(2)(b) provides that specified corporate governance requirements under Regulations 17 to 27, among other provisions, are not applicable to entities whose specified securities are listed on an SME Exchange, subject to the applicable regulatory framework.

Accordingly, the Corporate Governance Report does not form part of this Annual Report.



AUDITOR (S)

STATUTORY AUDITOR

In terms of the provisions of Section 139 of the Companies Act, 2013 and the Companies (Audit and Auditors) Rules, 2014, M/s Shiv & Associates, Chartered Accountants (ICAI Firm Registration No. 009989N), having registered office at Shop No. 67, First Floor, Sector-10 Market, Faridabad-121006, were appointed as the Statutory Auditors of the Company by the members/shareholders at the Sixth (06th) Annual General Meeting of the Company held on the 30th September 2025, for a period of five years i.e. up to the conclusion of Eleventh (11th) Annual General Meeting of the Company.

The Statutory Auditors' Report does not contain any qualification, reservation, adverse remark or disclaimer requiring explanation or comment by the Board, except as may be specifically stated in the Auditors' Report.

Further, pursuant to Section 143(12) of the Companies Act, 2013, the Statutory Auditors have not reported any fraud committed against the Company by its officers or employees, to the extent reported under the said provision.

SECRETARIAL AUDITOR

Pursuant to Section 204 of the Companies Act, 2013 and the rules made thereunder, the Board of Directors, at its meeting held on 28th March 2026, appointed M/s Amit K Mangla & Co., Company Secretaries in Practice (CP No. 23164), to conduct the Secretarial Audit of the Company for the financial year 2025-26.

The Secretarial Audit Report for the financial year ended 31 March 2026 is annexed to this Report as Annexure – B and forms an integral part of this Report.

The observations, qualifications, reservations or adverse remarks, if any, contained in the Secretarial Audit Report and the Company's comments thereon are set out in the relevant annexure to this Report.

INTERNAL AUDITOR

The Company has appointed M/s V C G & Co., Chartered Accountant as the internal auditor of the Company under section 138 of the Companies Act, 2013 read with Rule 13 of the Companies (Accounts) Rules, 2014.

The internal auditor of the company checks and verifies the internal control and monitors them in accordance with policy adopted by the company from time to time

DIRECTORS AND KEY MANAGERIAL PERSONNEL

There was no change in the composition of the Board of Directors of the Company during the financial year under review.

As on 31st March, 2026, the Board of Directors of KRM Ayurveda Limited comprises an optimum mix of Executive, Non-Executive and Independent Directors, as set out below:



S. No.	Name of Director	Designation	DIN
1	Mr. Puneet Dhawan	Managing Director	8553667
2	Mr. Sanchit Hans	Whole-Time Director	9228549
3	Mrs. Tanya Dhawan	Non-Executive Director	8553668
4	Mrs. Vandan Gupta	Independent Director	13488
5	Ms. Laxmi	Independent Director	10717921

During the financial year, Mr. Avtar Singh Rana was appointed as Chief Financial Officer of the Company w.e.f. 01st May, 2025.

BOARD MEETINGS

During the financial year 2025-26, 24 (Twenty-Four) Board Meetings were held.

The intervening gap between the Meetings was within the period prescribed under the Companies Act, 2013 and applicable regulations.

The dates of the meetings and attendance of the Directors are set out below:

S. No.	Date of Board Meeting	No. of Directors eligible to attend	No. of Directors attended meeting
1	29/04/2025	5	5
2	8/5/2025	5	5
3	19/5/2025	5	5
4	28/5/2025	5	5
5	16/6/2025	5	5
6	21/6/2025	5	3
7	2/7/2025	5	5
8	14/7/2025	5	5
9	17/7/2025	5	5
10	5/8/2025	5	5
11	20/8/2025	5	5
12	3/9/2025	5	5
13	11/9/2025	5	5
14	22/9/2025	5	5
15	10/10/2025	5	5

S. No.	Date of Board Meeting	No. of Directors eligible to attend	No. of Directors attended meeting
16	3/11/2025	5	5
17	4/12/2025	5	5
18	2/1/2026	5	5
19	8/1/2026	5	5
20	20/1/2026	5	5
21	27/1/2026	5	5
22	27/1/2026	5	5
23	24/2/2026	5	5
24	28/3/2026	5	5

NUMBER OF MEETINGS OF THE SHAREHOLDER(S) HELD DURING THE FINANCIAL YEAR 2025-26

S. No.	Date of EGM/AGM	Type of Meeting	No. of Shareholders eligible to attend	No. of Shareholders attended meeting
1	30.09.2025	AGM	44	15
2	13.05.2025	EGM	7	7
3	15.07.2025	EGM	44	15
4	21.08.2025	EGM	44	15
5	09.09.2025	EGM	44	15
6	29.12.2025	EGM	44	15

DECLARATION BY INDEPENDENT DIRECTORS

The Company has received the necessary declarations from the Independent Directors confirming that they meet the criteria of independence as prescribed under Section 149(6) of the Companies Act, 2013 and the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

The Independent Directors have also confirmed that they have complied with the requirements relating to inclusion of their names in the data bank maintained by the Indian Institute of Corporate Affairs, to the extent applicable.

COMMITTEES OF THE BOARD

The Board has constituted various committees to assist it in discharging its responsibilities effectively and to ensure good corporate governance practices.

The following Committees constituted by the Board function according to their respective roles and defined scope:

1. Audit Committee
2. Nomination and Remuneration Committee
3. Stakeholders' Relationship Committee
4. Independent Directors Committee



Audit Committee:

The Audit Committee was constituted vide Board Resolution dated 05th August, 2025 pursuant to section 177 of the Companies Act, 2013 and applicable provisions of the SEBI Listing Regulations.

The composition of the Audit Committee as on the date of this Report is as follows:

Name of Director	Designation of Committee	Nature of Directorship
Mrs. Vandana Gupta	Chairperson	Independent Director
Ms. Laxmi	Member	Independent Director
Mr. Puneet Dhawan	Member	Managing Director

The Company Secretary and Compliance Officer acts as the Secretary to the Committee.

The policy of the Audit Committee is available on the website of the Company at:
<https://www.krmayurvedaindia.com/>

During the Financial year 2025-2026, following meetings of the audit committee were held:

S. No.	Date	No. of members entitled to attend	No. of members attended
1	03.09.2025	3	3
2	11.09.2025	3	3

S. No.	Date	No. of members entitled to attend	No. of members attended
3	22.09.2025	3	3
4	04.12.2025	3	3
5	02.01.2026	3	3
6	08.01.2026	3	3
7	24.02.2026	3	3
8	28.03.2026	3	3

Nomination and Remuneration Committee:

The Nomination and Remuneration Committee was constituted vide Board Resolution dated 05th August, 2025 pursuant to Section 178 of the Companies Act, 2013 and applicable provisions of the SEBI Listing Regulations.

The composition of the Committee as on the date of this Report is as follows:

Name of Director	Designation of Committee	Nature of Directorship
Mrs. Vandana Gupta	Chairperson	Independent Director
Ms. Laxmi	Member	Independent Director
Mrs. Tanya Dhawan	Member	Director

The Company Secretary and Compliance Officer acts as the Secretary to the Committee.

The policy of the Nomination and Remuneration Committee is available on the website of the Company at: <https://www.krmayurvedaindia.com/>

During the Financial year 2025-2026, the following Nomination and Remuneration Committee meetings were held:

S. No.	Date	No. of members entitled to attend	No. of members attended
1	28.03.2026	3	3

Stakeholders' Relationship Committee:

The Stakeholders' Relationship Committee was constituted vide Board Resolution dated 05th August, 2025 pursuant to the applicable provisions of the Companies Act, 2013 and the SEBI Listing Regulations.

The composition of the Committee as on the date of this Report is as follows:

Name of Director	Designation of Committee	Nature of Directorship
Mrs. Vandana Gupta	Chairperson	Director
Ms. Laxmi	Member	Independent Director
Mr. Puneet Dhawan	Member	Managing Director

The Company Secretary and Compliance Officer acts as the Secretary to the Committee.

The policy of the Stakeholder Relationship Committee is available on the website of the Company at: <https://www.krmayurvedaindia.com/>

During the Financial year 2025-2026, following Stakeholder Relationship Committee were held:

S. No.	Date	No. of members entitled to attend	No. of members attended
1	28.03.2026	3	3

Independent Director Committee

During the financial year under review, the Board of Directors constituted an Independent Directors' Committee on 05th August, 2025 comprising only the Independent Directors of the Company. The Committee has been constituted to review and oversee matters specifically entrusted to it by the Board and applicable regulatory requirements, to ensure transparency, fairness, and protection of stakeholders' interests. The Committee functions in accordance with its terms of reference as approved by the Board and submits its recommendations to the Board for its consideration, wherever applicable.

Name of Director	Designation of Committee	Nature of Directorship
Mrs. Vandana Gupta	Chairperson	Independent Director
Ms. Laxmi	Member	Independent Director

During the Financial year 2025-2026, Independent Directors meeting was held on 24th February, 2026.

RSIK MANAGEMENT POLICY

The Company has established a framework for identifying, assessing, monitoring and mitigating various risks associated with its business and operations.

The major risks identified in the Company's business include, inter alia, regulatory risks, changes in consumer preferences, market competition, operational risks and other business-related risks.

The identified risks are periodically reviewed by the management and placed before the Audit Committee and/or Board, wherever considered appropriate.

The Board has adopted a Risk Management Policy setting out the framework for identification, assessment, monitoring and mitigation of risks.

PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES

All contracts and arrangements entered into with related parties during the financial year were in the ordinary course of business and, where applicable, on an arm's length basis and in compliance with the applicable provisions of the Companies Act, 2013 and the rules made thereunder.

The particulars of contracts or arrangements with related parties referred to in Section 188(1) of the Companies Act, 2013, in the prescribed Form AOC-2, are annexed to this Report as **Annexure – D** and form an integral part of this Report.

The Audit Committee and the Board of Directors have reviewed the related party transactions in accordance with the applicable provisions.

The Company has formulated a Related Party Transactions Policy, which is available on the Company's website at

https://www.krmayurvedaindia.com/documents/Policy_on_Related_Party_Transaction.pdf

SIGNIFICANT AND MATERIAL ORDER PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS IMPACTING THE GOING CONCERN STATUS AND COMPANY'S OPERATIONS IN FUTURE

During the financial year under review, the Company has not received any significant or material orders passed by any regulatory authority, court or tribunal which shall impact the going concern status and Company's operations in future.

INTERNAL FINANCIAL CONTROLS AND THEIR ADEQUACY

The Company has in place adequate internal financial control with reference to financial statements. The Board of Directors had earlier noted/approved the policies and procedures adopted by the Company for ensuring an orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information.

PREVENTION OF SEXUAL HARASSMENT AT WORKPLACE

The Company has adopted a policy on Prevention of Sexual Harassment at Workplace in accordance with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

The Company has constituted an Internal Complaints Committee ("ICC") for addressing complaints relating to sexual harassment at the workplace.

The Company has complied with the applicable provisions relating to constitution of the Internal Complaints Committee.

The details of complaints received and disposed of during the year are as follows:

No. of complaints received during the Financial year 2025-26 : Nil

No. of complaints disposed of during the Financial year 2025-26 : Nil

No. of complaints pending as on 31st March, 2026 : Nil

PREVENTION OF INSIDER TRADING

In compliance with the provisions of the Securities and Exchange Board of India (SEBI) (Prohibition of Insider Trading) Regulations, 2015, as amended, the Company has formulated and adopted the "Code of Conduct for prohibition of Insider Trading". The object of the Insider Trading Code is to set framework, rules and procedures which all concerned should follow, both in letter and spirit, while trading in the securities of the

Company. The Insider Trading Code is available at:

https://www.krmayurvedaindia.com/documents/Code_of_Conduct_for_Insider_Trading.pdf

VARIOUS POLICIES/ CRITERIA/ PROGRAMS etc.

In compliance with Companies Act, 2013 and Rules made there under, Listing Regulations and other applicable laws, the Board of Directors of your Company and its Committee/s at its respective meetings held on the 05th August, 2025, have duly reviewed and approved the following Policies/ Criteria/ Programs, and, the same are available on the website of the Company at i.e. https://www.krmayurvedaindia.com/KRMAL_Policies.php.

1. Policy on Preservation of Documents.
2. Committee of Board of Directors
3. Code of conduct for Insider Trading
4. Code of Conduct for Directors (Including Independent Directors) and Senior Management.
5. Code for Independent Directors
6. Whistle Blower Policy.
7. Terms and conditions of Independent Directors
8. Risk Management Policy
9. Criteria of making payment to Non-Executive Directors of the Company.
10. Material Litigation and material creditors
11. Policy for Familiarization Program of Independent Directors.
12. Policy on determining Material Subsidiary.
13. Policy on Sexual Harassment Policy.
14. Policy on Related Party Transactions.
15. Policy for determination of materiality of Events and Information

VIGIL MECHANISM/WHISTLE BLOWER POLICY

Pursuant to the provisions of section 177 (9) & (10) of the Companies Act, 2013, the Company has established a Vigil Mechanism/Whistle Blower Policy to enable Directors and employees to report genuine concerns, unethical behaviour, actual or suspected fraud, violations of the Company's Code of Conduct and other matters requiring attention.

The policy provides adequate safeguards against victimisation of persons who use the vigil mechanism and provides direct access to the Chairperson of the Audit Committee in appropriate or exceptional cases.

The Vigil Mechanism/Whistle Blower Policy has been uploaded on the website of the Company at https://www.krmayurvedaindia.com/documents/Whistle_Blower_Policy.pdf under "Investor Section".

POLICY ON CODE OF CONDUCT FOR DIRECTORS AND SENIOR MANAGEMENT

The Company has adopted a Code of Conduct for Directors and Senior Management Personnel, which is applicable to the members of the Board and Senior Management.

The Company has also adopted appropriate criteria and policies relating to appointment of Directors, qualifications, positive attributes, independence of Directors and remuneration of Directors, Key Managerial Personnel and other employees, as applicable.

The same are also available on the website of the Company at www.krmayurvedaindia.com at weblink https://www.krmayurvedaindia.com/documents/Code_of_Conduct_for_Board_of_Directors_and_Senior_Management.pdf

COMPLIANCE WITH SECRETARIAL STANDARDS

During the year under review, the Company was in compliance with the Secretarial Standards i.e., SS-1 and SS-2 relating to "Meeting of the Board of Directors" and "General Meetings" respectively.

LOANS, GUARANTEES AND INVESTMENTS

Details of loans, guarantees and investments under the provisions of Section 186 of the Companies Act, 2013 (the Act) read with the Companies (Meetings of Board and its Powers) Rules, 2014, as amended, from time to time, as on the 31st March, 2026, are set out in the Standalone Financial Statements forming part of this Annual report.

COMPLIANCE WITH MATERNITY BENEFIT ACT, 1961

The Company has complied with the provisions of the Maternity Benefit Act, 1961, including all applicable amendments and rules framed thereunder. The Company is committed to ensuring a safe, inclusive, and supportive workplace for women employees. All eligible women employees are provided with maternity benefits as prescribed under the Maternity Benefit Act, 1961, including paid maternity leave, nursing breaks, and protection from dismissal during maternity leave.

The Company also ensures that no discrimination is made in recruitment or service conditions on the grounds of maternity. Necessary internal systems and HR policies are in place to uphold the spirit and letter of the legislation

PARTICULARS OF FRAUDS REPORTED BY AUDITORS

During the financial year under review, the Statutory Auditors have not reported any fraud under Section 143(12) of the Companies Act, 2013, other than those which are reportable to the Central Government, to the extent applicable.

THE DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 DURING THE YEAR ALONG WITH THEIR STATUS AS AT THE END OF THE FINANCIAL YEAR

During the FY 2025-2026, no proceeding has been initiated under Insolvency and Bankruptcy Code for default in payment of debt. Further, the Company has also not initiated any proceedings against the defaulting entities.

DETAILS OF DIFFERENCE BETWEEN THE AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANK OR FINANCIAL INSTITUTIONS ALONG WITH THE REASONS THEREOF

During the period under review, there has been no one time settlement accordingly no valuation were done for this purpose.

PARTICULARS OF EMPLOYEES

The information required pursuant to Section 197 read with Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Amendment Rules, 2016 in respect of employees of the Company, is enclosed as **Annexure –E** and forms part of this Report.

Further, as per the provisions specified in Chapter XIII of Companies (Appointment & Remuneration of Managerial Personnel) Amendment Rules, 2016 no employees of the Company was in receipt of remuneration exceeding Rs. 1,02,00,000/- per annum, if employed for whole of the year or Rs. 8,50,000/- per month if employed for part of the year.

MATERIAL CHANGES AND COMMITMENTS, IF ANY, AFFECTING THE FINANCIAL POSITION OF THE COMPANY

Except as disclosed elsewhere in this Annual Report, there have been no material changes and commitments affecting the financial position of the Company between the end of the financial year 31 March 2026 and the date of this Report.

CORPORATE SOCIAL RESPONSIBILITY

The Company comes under the criteria as mentioned in section 135 of the Companies Act, 2013 i.e., Corporate Social Responsibility and accordingly the amount has been spent on CSR activities in the financial year 2025-2026 to comply with the requirements of necessary social expenditure. The CSR Report is annexed as **Annexure---F**

The Company is not required to constitute a Corporate Social Responsibility Committee since the amount required to be spent by the company on CSR activities for the financial year 2025-2026 does not exceed Rs.50,00,000/- (Rupees Fifty lakhs).

The CSR Policy of your Company outlines the Company's philosophy for undertaking socially useful programs for welfare and sustainable development of the community at large as part of its CSR Obligation.

DISCLOSURES

• Conservation of energy and technology absorption

The information relating to Conservation of Energy and Technology Absorption as required to be disclosed under Clause (m) of sub-section (3) of the Section 134 of the Companies Act, 2013, read with Rule 8 of the Companies (Accounts) Rules, 2014, is not applicable to your Company.

• Foreign Exchange Earnings and outgo

Information about the foreign exchange earnings and outgo, as required to be given under Clause (m) of sub-section (3) of the Section 134 of the Companies Act, 2013 read with Rule 8 of the Companies (Accounts) Rules, 2014, is given as follows:

Sl. No.	Particulars	For the Financial year ended on 31.03.2026	For the Financial year ended on 31.03.2025
(i)	<u>Expenditure in Foreign Currency.</u> Travelling expenses Imported Materials Purchase of Material Totalz	- - -	- - -
	Total	Nil	Nil
(ii)	<u>Earnings in Foreign Currency.</u> Sale of Flats/Plots/Farms etc.	Nil	Nil

COST RECORDS

The maintenance of cost records as specified by the Central Government under Section 148(1) of the Companies Act, 2013 is not applicable to the Company.

DIRECTOR'S RESPONSIBILITY STATEMENT

In accordance with the provisions of Section 134 of the Companies Act, 2013 ('the Act') with respect to Director's responsibility statement, the Directors confirm:

- in the preparation of the Annual Accounts for the Financial year ended 31st March, 2026, the applicable Indian Accounting Standards have been followed and no material departures have been made from the same;
- the Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as on the 31st March, 2026 and of the profit & loss incurred by of the Company for the year ended on that date;
- the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act

iv) safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

v) the Directors have prepared the annual accounts on a 'going concern' basis;

vi) the Directors have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and are operating effectively; and

vii) the Directors have devised proper systems to ensure compliance with the provisions of all applicable laws including applicable Secretarial Standards (SS-1 and SS-2) and that such systems are adequate and operating effectively.

PERFORMANCE EVALUATION OF THE BOARD, ITS COMMITTEES AND INDIVIDUAL DIRECTORS

The Company has established criteria for evaluation of the performance of the Board, its Committees and individual Directors in accordance with the applicable provisions of the Companies Act, 2013 and the SEBI Listing Regulations, as applicable.

During the financial year under review, the performance of the Board, its Committees and individual Directors was evaluated in accordance with the applicable framework and criteria adopted by the Company.

The evaluation covered various aspects, including Board composition, effectiveness of Board processes, participation in meetings, contribution of Directors, functioning of Committees and fulfilment of responsibilities.

The Independent Directors, wherever applicable, also carried out their separate evaluation in accordance with the applicable provisions of law.

SEBI COMPLAINTS REDRESS SYSTEM (SCORES)

The investor complaints are processed in a centralized web-based complaints redressal system. The salient features of this system are the centralized database of all complaints, online upload of Action Taken Reports (ATRs) by the concerned companies and online viewing by investors of actions taken on the complaint and its status. The Company has been registered on SCORES and makes every effort to resolve all investor complaints received through SCORES or otherwise within the statutory time limit from the receipt of the complaint. The Company has not received any complaints on the SCORES during the financial year 2025-2026.

ACKNOWLEDGEMENT

We would like to express their sense of gratitude to-

- all the regulatory authorities including SEBI, Stock Exchanges, Ministry of Corporate Affairs, Registrar of Companies and the Depositories.
- all the Bankers and Financial Institutions, the Central and State Governments as well as their respective Departments and Development Authorities in India and abroad connected with the business of the Company for their co-operation and continued support.
- the shareholders, depositors, suppliers, contractors and customers for the trust and confidence reposed by them in the Company.

The devoted teamwork and professionalism of the employees of the Company, at all levels are also very well appreciated. The employees continue to remain the Company's most valuable resources and their sustained hard work has enabled your Company to successfully meet the challenges during the year under review and that lie ahead.

Regd. Office:
A-16 G T Karnal Road Industrial Area,
Delhi-110033
CIN: L24239DL2019PLC354658

For and on behalf of the Board of Directors
of KRM Ayurveda Limited

Date: 03rd September, 2026
Place: New Delhi

Sd/-
(Puneet Dhawan)
Managing Director
DIN: 08553667

ANNEXURE-A

MANAGEMENT'S DISCUSSION AND ANALYSIS

GLOBAL ECONOMY – OVERVIEW

FY26 witnessed moderate global economic growth amid continuing geopolitical uncertainties, evolving trade dynamics, and inflationary pressures in several developed economies. While monetary tightening measures gradually eased across major economies, businesses continued to navigate volatility in commodity prices, supply chains, and financial markets.

Despite these challenges, the healthcare and wellness sectors remained resilient, supported by growing demand for preventive healthcare, natural remedies, nutritional supplements, and holistic wellness solutions. Increasing consumer focus on health and well-being continues to create significant opportunities for Ayurveda and traditional healthcare systems globally sustainable business operations.

INDIAN ECONOMY- OVERVIEW

FY 2025-26 was marked by continued resilience and robust growth in the Indian economy despite geopolitical uncertainties, fluctuating global commodity prices, and evolving international trade dynamics. India maintained its position among the world's fastest-growing major economies, supported by strong domestic consumption, sustained public investment, expanding digital infrastructure, and improving manufacturing capabilities.

The country's economic growth was driven by increasing consumer demand, rising urbanization, higher disposable incomes, and a favourable policy environment. Government initiatives focused on infrastructure development, digital transformation, financial inclusion, and entrepreneurship continued to strengthen the overall economic ecosystem. Public capital expenditure remained a key growth catalyst, encouraging private sector investments and enhancing economic productivity.

Inflationary pressures moderated during the year due to effective monetary measures, improved supply chain efficiencies, and stable commodity prices. The banking and financial services sector remained resilient, characterized by healthy credit growth, strong asset quality, and adequate liquidity, thereby supporting business expansion and consumer spending.

The healthcare, wellness, and AYUSH sectors continued to witness significant growth, driven by increasing awareness regarding preventive healthcare, natural remedies, holistic wellness, and lifestyle disease management. Consumer preference for Ayurvedic products, herbal formulations, nutraceuticals, and immunity-enhancing solutions remained strong across both urban and rural markets.

Government support through various initiatives aimed at promoting traditional medicine systems, strengthening the AYUSH ecosystem, encouraging research and innovation, and expanding access to quality healthcare further enhanced the growth prospects of the Ayurveda industry. Rising health consciousness, increasing digital adoption, and expanding e-commerce channels have also accelerated the penetration of Ayurvedic and wellness products across the country.

Against this backdrop, KRM Ayurveda Limited remains well-positioned to capitalize on the growing demand for Ayurveda-based healthcare and wellness solutions. The Company's focus on quality, innovation, customer trust, and market expansion continues to support its long-term growth strategy while contributing to the advancement of India's traditional healthcare ecosystem.

OUTLOOK

The outlook for the Indian economy remains positive and growth-oriented, supported by strong domestic consumption, continued infrastructure development, increasing digital adoption, and favorable government policies. India's position as one of the fastest-growing major economies is expected to be sustained in the coming years, driven by rising disposable incomes, urbanization, formalization of the economy, and increased investments across key sectors.

The healthcare, wellness, and AYUSH sectors are expected to remain among the key beneficiaries of these macroeconomic trends. Growing consumer awareness regarding preventive healthcare, holistic wellness, immunity enhancement, and lifestyle disease management continues to drive demand for Ayurvedic products and services. Increasing acceptance of natural and plant-based healthcare solutions among consumers is expected to further strengthen the growth prospects of the Ayurveda industry.

Government initiatives aimed at promoting traditional systems of medicine, strengthening the AYUSH ecosystem, supporting research and development, and enhancing healthcare accessibility are expected to create a conducive environment for industry

growth. The increasing integration of Ayurveda into mainstream healthcare, expansion of digital healthcare platforms, and growing penetration of e-commerce channels are likely to provide significant opportunities for companies operating in the sector.

The global wellness industry also continues to offer attractive growth opportunities. Rising health consciousness, increasing preference for natural healthcare products, and growing acceptance of traditional medicine systems across international markets are expected to support demand for Ayurvedic formulations and wellness solutions. India's emergence as a global hub for Ayurveda and wellness further enhances the long-term prospects for the industry.

At KRM Ayurveda Limited, we remain optimistic about the future and believe that the Company's strategic focus on quality, innovation, customer satisfaction, and market expansion positions it well to capitalize on emerging opportunities. The Company will continue to strengthen its product portfolio, enhance operational efficiencies, expand its customer reach, and explore new growth avenues in both domestic and international markets.

While global economic uncertainties, competitive pressures, regulatory changes, and fluctuations in raw material costs may pose certain challenges, the Company remains committed to maintaining a prudent and sustainable growth strategy. Leveraging its experience, brand strength, and commitment to delivering high-quality Ayurvedic and wellness solutions, KRM Ayurveda Limited is confident of creating long-term value for its customers, shareholders, employees, and other stakeholders.

INDUSTRY OVERVIEW – INDIAN AYURVEDIC PRODUCTS MARKET

The Indian Ayurvedic products market continued to demonstrate robust growth during FY 2025-26, driven by increasing consumer preference for natural healthcare solutions, preventive wellness, and holistic health management. Ayurveda has emerged as a mainstream healthcare and wellness segment, supported by favourable demographics, rising disposable incomes, and growing awareness of healthy lifestyles.

Key Industry Growth Drivers

1. Rising Consumer Preference for Natural Products

- Increasing awareness regarding the side effects associated with prolonged use of synthetic products has led consumers to adopt herbal and Ayurvedic alternatives.
- Demand for plant-based, chemical-free, and naturally sourced products continues to rise across healthcare, personal care, and nutrition segments.

2. Growing Focus on Preventive Healthcare

- Consumers are increasingly prioritizing preventive healthcare and wellness over curative treatment.
- Rising incidences of lifestyle-related disorders such as diabetes, obesity, stress, and cardiovascular diseases have strengthened the demand for Ayurvedic formulations and wellness solutions.

3. Government Support for the AYUSH Sector

- Continued policy support from the Government of India through the Ministry of AYUSH has enhanced the visibility and acceptance of traditional medicine systems.
- Initiatives focused on research, standardization, quality control, and promotion of Ayurveda are creating a favourable industry environment.

4. Expansion of Digital and E-Commerce Channels

- Growth of e-commerce platforms and digital healthcare channels has significantly improved product accessibility and consumer reach.
- Digital marketing and online consultations have enabled Ayurvedic companies to engage directly with customers across geographies.

5. Increasing Global Acceptance of Ayurveda

- Growing international awareness regarding holistic wellness and natural healthcare has expanded export opportunities for Indian Ayurvedic products.
- Ayurveda continues to gain recognition as an alternative and complementary healthcare system in various global markets.

6. Product Innovation and Diversification

- Companies are increasingly focusing on developing innovative products across categories such as Ayurvedic medicines, nutraceuticals, immunity boosters, herbal supplements, personal care products, and wellness solutions.
- Research-driven product development is helping improve consumer acceptance and market penetration.

STRATEGIC ALIGNMENT

KRM Ayurveda Limited continues to align its business strategy with the growing demand for ayurvedic and natural healthcare products. The company remains focused on strengthening its product portfolio, expanding market reach, enhancing brand visibility, and maintaining high standards of quality and regulatory compliance.

Key Strategic Priorities Include:

- Expanding and diversifying ayurvedic and wellness product offerings.
- Strengthening distribution channels, including retail and digital platforms.
- Enhancing product quality through continuous improvement and innovation.
- Improving operational efficiencies and cost optimization.
- Leveraging digital initiatives to increase customer engagement and market penetration.
- Promoting sustainable growth through strong governance and responsible business practices.

With increasing consumer preference for preventive healthcare and natural wellness solutions, KRM Ayurveda Limited is well-positioned to capitalize on emerging opportunities and drive long-term value creation for its stakeholders.

INDIAN HEALTH & WELLNESS INDUSTRY

The Indian health and wellness industry continues to witness robust growth, driven by increasing health consciousness, rising disposable incomes, urbanization, changing lifestyles, and growing consumer preference for preventive healthcare. Consumers are increasingly shifting from curative healthcare solutions toward wellness-oriented products that support immunity, nutrition, fitness, personal care, and holistic well-being.

The COVID-19 pandemic accelerated awareness regarding preventive healthcare, resulting in sustained demand for products focused on immunity enhancement, nutritional supplementation, herbal healthcare, and natural wellness solutions. This trend has strengthened consumer acceptance of traditional systems such as Ayurveda, which are increasingly being integrated into mainstream healthcare and wellness practices. The immunity segment remains one of the largest categories within the health and wellness market, supported by growing adoption of herbal and plant-based products.

India's nutraceutical and wellness sector is emerging as one of the fastest-growing segments within the consumer health industry. Rising prevalence of lifestyle-related ailments such as diabetes, obesity, cardiovascular disorders, stress, and digestive health

concerns has encouraged consumers to adopt preventive healthcare products. The market is witnessing strong demand for functional foods, dietary supplements, herbal formulations, and Ayurveda-inspired products. Consumer preference is increasingly shifting toward natural, clean-label, and plant-based solutions, creating significant opportunities for Ayurveda-focused companies.

The Ayurveda sector continues to benefit from India's rich heritage of traditional medicine, increasing government support for AYUSH initiatives, expanding consumer awareness, and growing acceptance among younger demographics. The industry is also witnessing increasing investments, product innovation, scientific validation, and expansion into new wellness categories such as nutraceuticals, personal care, immunity, gut health, and lifestyle management. Recent strategic acquisitions and investments by leading FMCG players in Ayurvedic and wellness businesses further underscore the long-term growth potential of the sector. Digital commerce, modern retail channels, and direct-to-consumer (D2C) platforms have significantly improved product accessibility across urban and semi-urban markets. Consumers today seek transparency, efficacy, quality assurance, and scientifically backed formulations, encouraging companies to invest in research, innovation, and brand building. The convergence of traditional Ayurveda with modern science presents substantial opportunities for companies operating in the health and wellness ecosystem.

EMERGING TRENDS

The Indian wellness and AYUSH sector continues to witness significant transformation, driven by changing consumer preferences, technological advancements, and supportive government initiatives. The following trends are shaping the future of the industry and creating new opportunities for KRM Ayurveda Limited:

A. Increasing Preference for Preventive and Integrative Healthcare

Healthcare consumers are increasingly adopting a preventive approach towards health management, with greater emphasis on nutrition, Ayurveda, yoga, naturopathy, and holistic wellness practices. This shift reflects a growing awareness of lifestyle-related disorders and a preference for integrated healthcare solutions that focus on long-term well-being rather than episodic treatment. The trend aligns well with KRM Ayurveda Limited's vision of promoting holistic and sustainable healthcare solutions.

B. Growth of Wellness Tourism

India is emerging as a preferred global destination for wellness tourism, supported by its rich heritage in Ayurveda, yoga, and traditional healing systems. Wellness retreats, Ayurvedic treatment centres, yoga destinations, and holistic healthcare facilities are attracting both domestic and international visitors. With wellness tourism growing at a faster pace than the broader wellness market, the segment presents substantial growth opportunities for AYUSH-focused healthcare providers.

C. Digitalization and Expansion of Tele-AYUSH Services

The adoption of digital technologies is transforming the delivery of healthcare services across the AYUSH ecosystem. Government-led initiatives promoting telemedicine, digital health platforms, and e-health services are expanding access to Ayurvedic consultations and treatments, particularly in underserved regions and international markets. The growing acceptance of digital healthcare solutions is expected to enhance patient engagement and improve service accessibility.

D. Emergence of an Organized and Quality-Focused Industry

Consumers are increasingly seeking certified, credible, and evidence-based healthcare and wellness providers. Enhanced regulatory oversight, accreditation of AYUSH Health and Wellness Centres (AHWCs), investments in research and development, and improvements in AYUSH education are contributing to higher standards across the industry. This trend is fostering greater trust in organized players and encouraging the adoption of quality-driven healthcare services.

E. Rising Demand for Corporate Wellness Solutions

Corporate wellness has emerged as a rapidly growing segment as organizations increasingly recognize the importance of employee health, productivity, and overall well-being. Companies are investing in preventive healthcare programs, stress management initiatives, yoga and wellness sessions, and holistic healthcare solutions. The continued expansion of the corporate wellness market is expected to create new avenues for AYUSH-based healthcare providers and wellness service companies.

KRM Ayurveda Limited remains well-positioned to capitalize on these emerging trends through its focus on Ayurvedic healthcare services, wellness initiatives, quality patient care, and strategic expansion of its healthcare infrastructure.

KEY OPPORTUNITIES

A. Expanding Opportunities in Wellness and Ayurvedic Healthcare

The growing acceptance of Ayurveda and holistic healthcare presents significant opportunities for KRM Ayurveda Limited to expand its healthcare and wellness offerings. Rising consumer awareness regarding preventive healthcare, natural therapies, and lifestyle management is driving demand for integrated Ayurvedic treatment solutions, enabling the Company to strengthen its market presence and service portfolio.

B. Expansion of Ayurvedic Healthcare Infrastructure

Government initiatives aimed at strengthening the AYUSH ecosystem, including the development of AYUSH Health and Wellness Centres (AHWCs) under the Ayushman Bharat programme, are expected to enhance public access to traditional healthcare services. These initiatives provide opportunities for KRM Ayurveda Limited to expand its healthcare outreach, participate in community health programmes, and extend Ayurvedic treatment services to underserved regions.

C. Digital Healthcare and Tele-Consultation Services

The increasing adoption of telemedicine and digital health platforms offers substantial opportunities to broaden patient access and improve healthcare delivery. By leveraging digital consultation services, online patient engagement platforms, and technology-enabled healthcare solutions, KRM Ayurveda Limited can expand its reach beyond physical locations and provide continuous care to patients across geographies.

D. Growth in Wellness Tourism and Integrative Healthcare Services

India's emergence as a global wellness destination is creating new opportunities for Ayurveda-based healthcare providers. Growing interest among domestic and international visitors in Ayurvedic therapies, wellness retreats, rejuvenation programmes, and holistic healing solutions presents an attractive avenue for future growth. KRM Ayurveda Limited is well-positioned to benefit from this trend through its integrated healthcare and wellness offerings.

E. Increasing Preference for Quality-Assured Healthcare Providers

Consumers are increasingly seeking trusted, compliant, and quality-driven healthcare institutions. Enhanced regulatory standards, accreditation frameworks, and growing emphasis on evidence-based healthcare practices are fostering confidence in organized players. KRM Ayurveda Limited's focus on quality healthcare services, patient-centric care, and adherence to regulatory requirements positions the Company favorably to capitalize on this evolving market preference.

F. Rising Demand for Corporate Wellness Solutions

The increasing focus on employee health and workplace well-being has led to growing demand for corporate wellness programmes. Organizations are investing in preventive healthcare initiatives, stress management programmes, yoga sessions, and holistic wellness solutions. This trend presents opportunities for KRM Ayurveda Limited to develop customized wellness offerings and strengthen its presence in the corporate healthcare segment.

The Company remains committed to leveraging these opportunities through strategic expansion, healthcare innovation, digital initiatives, and continued focus on delivering high-quality Ayurvedic healthcare services.

KEY THREATS AND CHALLENGES

While the long-term outlook for the Ayurveda and wellness industry remains positive, the sector continues to face certain challenges that may impact growth and profitability. KRM Ayurveda Limited remains vigilant and proactive in addressing these risks through robust operational and strategic initiatives.

A. Intensifying Industry Competition

The Ayurveda and wellness sector is witnessing increasing participation from established healthcare companies, wellness chains, hospitals, digital health platforms, and emerging start-ups. Heightened competition may exert pressure on pricing, patient acquisition, market share, and service differentiation, requiring continuous innovation and quality enhancement.

B. Regulatory and Compliance Risks

The healthcare and AYUSH sectors operate within a stringent regulatory framework. Changes in government policies, healthcare regulations, licensing requirements, clinical protocols, or compliance standards may necessitate additional investments and operational adjustments. Non-compliance could adversely affect business operations and reputation.

C. Availability and Retention of Skilled Professionals

The Company's growth depends significantly on the availability of qualified Ayurvedic doctors, therapists, healthcare professionals, and support staff. Increasing competition for skilled talent across the healthcare industry may create challenges in recruitment, retention, and workforce development.

D. Changing Consumer Preferences and Expectations

Healthcare consumers are becoming increasingly informed and quality-conscious, demanding evidence-based treatments, personalized care, digital engagement, and superior patient experiences. Failure to adapt to evolving consumer expectations may impact the Company's ability to attract and retain patients.

E. Technology and Cybersecurity Risks

The growing adoption of digital healthcare platforms, tele-consultation services, and electronic patient management systems exposes healthcare providers to cybersecurity threats, data privacy concerns, and technology-related disruptions. Protecting patient information and ensuring secure digital operations remain critical priorities.

F. Dependence on Economic Conditions

Demand for certain wellness and preventive healthcare services may be influenced by overall economic conditions, consumer spending patterns, and discretionary income levels. Economic uncertainties could impact patient footfalls and spending on elective wellness services.

G. Supply Chain and Raw Material Availability

The Ayurveda sector relies on the timely availability of quality herbal ingredients, medical consumables, and healthcare supplies. Supply chain disruptions, fluctuations in raw material costs, or quality-related issues may affect operational efficiency and service delivery.

H. Reputation and Service Quality Risks

Healthcare organisations operate in a highly trust-driven environment. Any adverse event relating to patient care, service quality, regulatory compliance, or public perception could impact the Company's reputation and stakeholder confidence. Maintaining high standards of clinical governance and patient satisfaction remains essential.

I. Expansion and Operational Execution Risks

As the Company continues to expand its healthcare infrastructure and service offerings, successful execution of expansion plans, efficient resource allocation, and effective management of new facilities remain critical. Delays in implementation or operational inefficiencies may affect anticipated returns on investment.

KRM Ayurveda Limited continuously evaluates these risks and has established appropriate internal controls, governance mechanisms, and risk management practices to mitigate their potential impact and support sustainable long-term growth.

CONCLUSION

The healthcare and wellness industry in India continues to offer significant growth opportunities, supported by increasing awareness of preventive healthcare, rising acceptance of Ayurveda and traditional systems of medicine, favorable government initiatives, and the growing demand for holistic wellness solutions. These developments are creating a conducive environment for the expansion of organized AYUSH healthcare services across the country.

Looking ahead, the Company remains committed to leveraging emerging opportunities in Ayurvedic healthcare, wellness services, digital healthcare solutions, and preventive medicine. By focusing on operational excellence, quality healthcare delivery, regulatory compliance, technological adoption, and continuous innovation, KRM Ayurveda Limited aims to strengthen its market position and expand its footprint in the rapidly evolving healthcare landscape.

While the Company remains mindful of industry challenges, competitive pressures, and regulatory developments, it is confident that its strategic direction, experienced management team, and patient-centric approach will support sustainable growth and long-term stakeholder value creation.

KRM Ayurveda Limited remains dedicated to its mission of promoting holistic health and wellness through authentic Ayurvedic healthcare solutions and is well-positioned to capitalize on the opportunities emerging within the healthcare and wellness sector.

COMPANY OVERVIEW

KRM Ayurveda Limited ("KRM Ayurveda" or "the Company") is engaged in the Ayurvedic healthcare and wellness sector, with a focus on providing holistic, preventive and patient-centric healthcare solutions based on the principles of Ayurveda.

The Company seeks to combine the traditional knowledge and principles of Ayurveda with contemporary healthcare practices, professional clinical standards, technology-enabled processes and patient-centric service delivery. Its objective is to develop a trusted healthcare platform focused on quality treatment, preventive healthcare, wellness and long-term patient well-being.

During FY 2025-26, the Company undertook strategic initiatives to strengthen its presence in the healthcare sector. The Company remains focused on building its healthcare infrastructure, strengthening clinical capabilities, enhancing patient experience, adopting appropriate technology, and developing

Financial Highlights

Particulars	<u>FY26</u>	<u>FY25</u>	<u>Ratio</u>
Revenue(in ₹ Crore)	101.69	76.55	33%
EBITDA (in ₹ Crore)	31.12	19.14	63%
EBITDA Margin (in %)	30.60	25.00	–
PAT (in ₹ Crore)	20.12	11.21	79%
PAT Margin (in %)	19.79	14.65	–
Net Worth (in ₹ Crore)	114.71	23.90	380%

Key Financial Ratios

Particulars	<u>FY26</u>	<u>FY25</u>	<u>% Change</u>
Current Ratio	13.82	1.65	735.64%
Debt-Equity Ratio	0	1.31	-100.00%
Debt-Service Coverage Ratio	9.57	6.60	44.97%
Return on Equity Ratio	0.29	0.61	-52.65%
Inventory Turnover Ratio	12.16	16.74	-27.37%
Trade Receivables Turnover Ratio	5.83	8.67	-32.68%
Trade Payables Turnover Ratio Net	3.74	3.42	9.39%
Capital Turnover Ratio	1.16	4.98	-76.63%
Net Profit Ratio	19.79%	14.65%	35.06%
Return on Capital Employed	26.13%	42.56%	-38.59%

Reason for Change in Ratio (more than 10%)

1. Current Ratio – Increase in Ratio due to IPO Proceeds amount included in the Current Assets.
2. Debt-Equity Ratio – Decrease in ratio on account of decrease in Debt and increase in Shareholders Equity.
3. Debt-Service Coverage Ratio – Increase in ratio on account of increase in Profits during the year and decreased in debts.
4. Return on Equity Ratio – Decrease in ratio on account of increase in shareholders equity during the year.
5. Inventory Turnover Ratio – Decrease in ratio due to increase in revenue.
6. Trade Receivables Turnover Ratio – Decrease in ratio due to increase in trade receivables and revenue.
7. Net Capital Turnover Ratio – Decrease in ratio due to reduction in Company net working capital position (Current Asset – Current Liability).
8. Net Profit Ratio – Increase in ratio on account of Increase in Profit during the year.
9. Return on Capital Employed – Decrease in ratio on account of increase in shareholders equity during the year.

RISK MANAGEMENT

The Company recognizes that effective risk management is essential for sustainable growth.

The Company periodically evaluates business, operational, financial, regulatory, clinical, technology and reputational risks and seeks to establish appropriate processes and controls to mitigate such risks.

Key risk management focus areas include:

- Regulatory and statutory compliance;
- Financial controls and reporting;
- Clinical and patient-care processes;
- Human resource management;
- Information security and data protection;
- Vendor and supply-chain management;
- Infrastructure and operational continuity;
- Reputation management; and
- Business expansion and execution.

The Company's risk management framework should continue to evolve in line with the scale and complexity of its operations.

INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY

The Company maintains internal control systems and processes commensurate with the nature, scale and complexity of its operations.

The internal control framework is designed to provide reasonable assurance regarding:

- Accuracy and reliability of financial reporting;
- Safeguarding of assets;
- Proper authorization and recording of transactions;
- Operational efficiency;
- Compliance with applicable laws and regulations;
- Identification and mitigation of business risks; and
- Prevention and detection of errors and irregularities.

The Company's internal controls are supported by appropriate policies, approval mechanisms, segregation of responsibilities, financial controls and periodic management reviews.

The adequacy and effectiveness of internal controls are reviewed periodically by the management and through the Company's internal audit and other assurance mechanisms, as applicable.

HUMAN RESOURCES AND INDUSTRIAL RELATIONS

Human resources are an important component of the Company's healthcare operations.

The Company's ability to deliver quality Ayurvedic healthcare services depends on qualified and experienced doctors, therapists, nursing personnel, healthcare professionals, administrative personnel and support staff.

During FY 2025-26, the Company focused on building the human resource capabilities required for its healthcare operations.

The Company seeks to foster a professional, ethical and patient-centric work environment and encourages continuous learning and development.

The Company also remains committed to maintaining appropriate workplace practices, employee welfare, professional conduct and compliance with applicable labour and employment requirements.

Total number of employees as at March 31, 2026: 431.

TECHNOLOGY AND DIGITAL INITIATIVES

Technology is expected to play an increasingly important role in the Company's healthcare operations.

The Company intends to leverage appropriate digital solutions for:

- Patient appointment management;
- Digital communication;
- Healthcare records and documentation;
- Patient follow-up;
- Tele-consultation, where appropriate;
- Administrative efficiency;
- Management reporting; and
- Customer engagement.

The Company will continue to evaluate technology initiatives based on their relevance, cost-effectiveness, scalability, security and potential to improve patient experience.

QUALITY, PATIENT CARE AND REGULATORY COMPLIANCE

The Company recognizes that quality healthcare delivery and regulatory compliance are fundamental to its long-term success.

The Company is committed to maintaining appropriate standards relating to patient care, healthcare practices, professional conduct, infrastructure, hygiene, safety, documentation and applicable regulatory requirements.

The Company also seeks to strengthen processes relating to patient feedback and service improvement.

As the healthcare operations scale, the Company will continue to review and enhance its quality-management practices in line with applicable requirements and industry standards.

ENVIRONMENT, SOCIAL RESPONSIBILITY AND RESPONSIBLE BUSINESS PRACTICES

The Company recognizes the importance of responsible business practices and seeks to conduct its operations with due regard to environmental, social and governance considerations.

The Company aims to promote:

- Ethical and responsible healthcare practices;
- Patient safety and well-being;
- Employee welfare;
- Responsible resource utilization;
- Compliance with applicable laws;
- Transparent governance; and
- Responsible engagement with stakeholders.

Where applicable, the Company will progressively strengthen its sustainability initiatives in line with the scale and nature of its operations.

FORWARD-LOOKING STATEMENTS

This Management Discussion and Analysis contains statements concerning the Company's objectives, expectations, estimates, projections and outlook that may constitute forward-looking statements within the meaning of applicable securities laws and regulations.

These statements are based on management's current expectations and assumptions and are subject to various risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied.

Important factors that may affect the Company's operations and financial performance include changes in economic conditions, healthcare demand, competition, regulatory and government policies, availability of qualified professionals, operating costs, technology-related risks, patient preferences, business execution, litigation and other factors beyond the Company's control.

The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as may be required under applicable laws and regulations.

**Regd. Office: A-16 G T Karnal Road Industrial Area,
Delhi-110033**

CIN: L24239DL2019PLC354658

Date: 03rd September, 2026

Place: New Delhi

For and on behalf of the Board

For KRM Ayurveda Ltd.

Sd/-

(Puneet Dhawan)

Managing Director

(DIN: 08553667)

ANNEXURE TO DIRECTORS' REPORT
ANNEXURE-B

Form No. MR-3
Secretarial Audit Report
(For the Financial year ended 31st March, 2026)

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,

The Members
KRM Ayurveda Limited
A-16, GT Karnal Road,
Industrial Area,
New Delhi – 110033

We were appointed by the Board of Directors of KRM Ayurveda Limited (hereinafter called “the Company”) to conduct the Secretarial Audit for the Financial year 2025-26.

A. Management’s Responsibility on Secretarial Compliances

The Company’s Management is responsible for the preparation and maintenance of the secretarial records and for devising proper systems to ensure compliance with the provisions of applicable laws and regulations.

B. Auditor’s Responsibility

Our responsibility is to express an opinion on the secretarial records, standards and procedures followed by the Company with respect to secretarial compliances. We believe that audit evidence and information obtained from the Company’s management is adequate and appropriate for us to provide a basis for our opinion.

C. OPINION

1) We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by the Company. Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

2) Based on our verification of the books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit and we hereby report that in our opinion, the Company has during the audit period covering the Financial period ended on the 31st March, 2026, complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and Compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I. The Companies Act, 2013 (the Act) and the Rules made thereunder, as applicable;

II. The Secretarial Standard with respect to Meetings of Board of Directors (SS-1) and General Meetings (SS-2) issued by the Institute of Company Secretaries of India;

III. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made thereunder;

IV. The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;

V. Foreign Exchange Management Act, 1999 and the Rules and Regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings; **Applicable to the Company during the review period.**

VI. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'): -

a) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable to the Company with effect from the listing of its Equity Shares on the NSE SME Platform on January 29, 2026;;

b) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended;

- c) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended;
- d) The Securities and Exchange Board of India (Issue of Capital and Disclosures Requirements) Regulations, 2018; – **Not applicable as the Company has not issued further shares during the Financial year under review;**
- e) The Securities and Exchange Board of India (Share based Employee benefits and Sweat Equity) Regulations, 2021 in relation to Employee Stock Option Scheme; – **Not applicable as the Company has not issued any ESOP during the Financial year under review.**
- f) The provisions of Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008 – **Not applicable to the Company during the Financial year under review.**
- g) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client; – **Not applicable as the Company is not registered as Registrar to an Issue and Share Transfer Agent during the Financial year under review.**
- h) The Securities and Exchange Board of India (Delisting of Equity Shares) regulations, 2021; – **Not applicable.**
- i) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; – **Not applicable.**

VII. Other laws as applicable to the Company.

We further report that:

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors, wherever applicable.

Adequate notice was given to all Directors to schedule the Board Meetings. Agenda and detailed notes on agenda were sent in advance and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meetings and for meaningful participation at the meetings.

All decisions at Board Meetings and Committee Meetings were carried out unanimously / with requisite majority as recorded in the minutes.

We further report that there are adequate systems and processes in the Company commensurate with its size and operations to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that during the audit period the following events/actions had a major bearing on the Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards etc.:

1. Appointment of Chief Financial Officer (CFO) during the year, and other appointment(s)/re-appointment(s) of Key Managerial Personnel, Directors and Auditors, wherever applicable.
 2. Increase in the Authorized Share Capital of the Company during the year.
 3. Bonus Issue of Equity Shares and allotment thereof during the year.
 4. Private Placement of securities and allotment thereof during the year.
 5. Initial Public Offer of 57,40,000 equity shares on the NSE SME Platform, and allotment of securities on January 27, 2026.
 6. Listing of Equity Shares on NSE SME Platform on January 29, 2026
 1. Public Issue / IPO-related compliances and allotment of securities.
 1. Appointment/Re-appointment of Key Managerial Personnel, Directors and Auditors, wherever applicable. 1.
- Other material events, if any.

For Amit K Mangla & Company
Practicing Company Secretaries

Sd/-
Amit Kumar Mangla
(Proprietor)
FCS No. 11450, CP No.: 23164
Peer Review Certificate No. 4032/2023
UDIN: F011450H001355419

Date: 03.09.2026 Place: Faridabad

This report is to be read with our letter of even date which is annexed as "Annexure A" and forms an integral part of this report.

Annexure A

To,

KRM Ayurveda Limited A-

16, GT Karnal Road,
Industrial Area,
New Delhi – 110033

Our report of even date is to be read along with this letter.

1. Maintenance of secretarial records is the responsibility of the management of the Company. Our responsibility is to express an opinion on these Secretarial Records based on our audit.
2. We have followed the audit practices and processes as we were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial Records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Wherever required, we have obtained the Management representation about the compliance of laws, rules, and regulations and the happening of events etc.
5. The Compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit Report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

**For Amit K Mangla &
Company Practicing
Company Secretaries**

Sd/-

**Amit Kumar Mangla
(Proprietor)**

FCS No. 11450, CP No.: 23164 Peer Review Certificate No. 4032/2023

UDIN: F011450H001355419

Date: 03.09.2026

Place: Faridabad

**(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of
the Companies (Accounts) Rules, 2014**

Form for Disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arm's length transaction under third proviso thereto.

1. Details of contracts or arrangements or transactions not at Arm's length basis: All contracts/arrangements entered into by the Company with related parties referred to in sub-section (1) of Section 188 of the Companies Act, 2013 are at arm's length basis.

2. Details of material contracts or arrangement or transactions at arm's length basis: All the transactions (non-material and material, if any as stated in financials) were entered by the Company in ordinary course of business and were in arm's length basis:

Name of the Related Party	Nature of Relationship	Nature of contract/agreement/ transactions	Duration of contract/agreement/ transactions	Salient terms of contracts or agreements, or transactions including the value	Date(s) of approval by the Board, if any:
Tanya Dhawan	Director	Consultancy Fees	Ongoing Transactions (year on year)	Services availed	04.12.2025
Puneet Dhawan	Director	Royalty	Transactions For FY 2028-29. (3 year)	Services availed	04.12.2025
Puneet Dhawan	Director	Rent Paid	Transactions For FY 2026-27. (1 year)	Rent Paid	04.12.2025
Som Dev Dhawan	Director's Father (Mr. Puneet Dhawan)	Rent Paid	Transactions For FY 2026-27. (1 year)	Rent Paid	04.12.2025
Karma Life Care LLC	Entity Under Significant Control	Sales	Ongoing Transactions (year on year)	Sale of Goods & Services	04.12.2025
Karma Online Services LLC	Entity Under Significant Control	Sales	Ongoing Transactions (year on year)	Sale of Goods & Services	04.12.2025

All the transactions were entered by the Company in ordinary course of business and were in arm's length basis:

The Company has entered into contracts or arrangements with related parties as referred to in Section 188(1) of the Companies Act, 2013. However, all such transactions are entered into in the ordinary course of business and in the option of the Board all such transaction are at arm's length. Accordingly, the requisite approval(s) of the Board of Directors, the relevant Committee(s), and/or the Shareholders, as applicable, have been obtained in accordance with the provisions of the applicable law.

KRM Ayurveda Limited
(Formerly known as KRM Ayurveda Private Limited)

Date: 03.09.2026
Place: New Delhi

Sd/-
Puneet Dhawan
Managing Director
DIN: 08553667
Address: House No. 9, Block-B,
Mahatam Gandhi Road, Adarsh
Nagar, Delhi-110033

Sd/-
Sanchit Hans Whole-
Time Director DIN:
09228549
Address: H. No 288, Rajdhani
Enclave, Pitam Pura Saraswati
Vihar, Delhi-110034

ANNEXURE-D

ANNEXURE TO DIRECTORS' REPORT

Statement of Disclosure of Remuneration under Section 197(12) of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

- i. Ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the Financial year 2025-26 and the percentage increase in remuneration of each Director, Chief Executive Officer, Chief Financial Officer and Company Secretary during the Financial year 2025-26: -

Sr. No.	Name of Director/KMP	Designation	Ratio of remuneration of each Director to median remuneration of employees	Percentage increase/decrease in Remuneration (in %)
1	Mr. Puneet Dhawan	Managing Director	30.6:1	-
2	Mr. Sanchit Hans	Whole Time Director	7.4:1	11%
3	Mrs. Tanya Dhawan	Non- Executive Director	0	-
4	Mrs. Vandana Gupta	Independent Women Director	0	-
5	Ms. Laxmi	Independent Women Director	0	-
6	Mr. Avtar Singh Rana	CFO	1.5:1	-
7	Ms. Pooja Garg	Company Secretary	3.9:1	-

Notes:

- I. The median remuneration of the Company for all its employees is INR 22,875 per month for the financial year 2025-2026.
- II. There was an increase of 13.47 % in the median remuneration of employees in the financial year 2025-26;
- III. The Company has 431 permanent employees on its rolls as on the 31st March, 2026;
- IV. Average percentage increase made in the salaries of employees other than the managerial personnel in the financial year was approx. 11%, and there was increase in the managerial remuneration by 3%;
- V. It is hereby affirmed that the remuneration paid during the financial year is as per the Remuneration Policy of the Company.

Regd. Office:**A-16 G T Karnal Road Industrial Area,****Delhi-110033****CIN: L24239DL2019PLC354658****Date: 03rd September, 2026****Place: New Delhi****For and on behalf of the Board of Directors of
KRM Ayurveda Limited****Sd/-****(Puneet Dhawan)****Managing Director****DIN: 08553667**

ANNEXURE TO DIRECTORS' REPORT

ANNEXURE – E

Particulars of employees as required Section 197(12) of the Act read with Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and forming part of the Directors' Report for the period ended the 31st March, 2026.

TOP TEN EMPLOYEES								
Name of Employees/Directors	Designation of Employee/ Nature of Employment	Age (Years)	Gross Remuneration accrued / received (Rs.)	Qualification	Experience (Years)	Date of Commencement of Employment	Previous Employment	Period during which post held in last employment
Puneet Dhawan	Managing Director	39	8,400,000	Bachelor of Ayurvedic Medicine & Surgery	13	3/9/2019	-	-
Himanshu Shekhar Tiwari	President (Technical)	52	2,854,586	M.D, MBA	25	24/5/2023	Multani Pharmaceutical	18 Years Head R&D & Medical Advisor
Tarun Batra	VP	39	2,480,856	MBA	15	1/5/2022	Infoedge India Limited	Sr. Manager
Sanchit Hans	Whole Time Director	30	2,035,200	Bachelor of Commerce	5	24/2/2023	-	-
Prashanti Chaudhary	Vice President (Sales)	30	1,792,824	B. Tech	9	1/6/2021	Ionizer Systems Pvt. Ltd.	Operations Manager
Rachna Hans	Brand Strategic	54	1,379,888	MBA (Marketing)	15	3/2/2022	-	-
Neeta Tiwari	QA	47	1,203,738	BSC	5	24/5/2023	Tiwari & Tiwari Associates	Auditor

Dr. Jyoti Sadasivan	COS	33	1,158,810	BAMS	9.5	20/6/2021	Jiva Ayurveda	Sr. Ayurveda Consultant
Pooja Garg	Compliance Officer	37	1,071,000	CS, MBA, M. Com	7+	10/3/2025	MBC Legal Advisors Private Limited	Manager of Secretarial Team
Jitender Kumar	Operation Manager	40	1,064,800	B.A.	19	1/9/2020	I-QOR IND PVT. LTD.	Team Leader

NOTES: -

a) Gross remuneration includes Basic Salary, House/HRA, reimbursement and Employer's contribution to Provident Fund and Family Pension Fund, L.T.A., club fees, electricity, gas, water & furnishing expenses, personal accident insurance and commission, wherever applicable, also includes monetary value of perquisites (like, Use of Motor car with Chauffeur, Provision of sweeper/gardener/watchman, etc.) on the basis of the Income Tax Act and Rules. Also entitled to gratuity.

b) There is no employee who holds by himself or along with his spouse and dependent children, not less than 02% Equity shares of the Company and has been in receipt of remuneration in excess of that drawn by the Whole-Time Director or Managing Director of the Company. Employees mentioned aforesaid, as on 31st March, 2026, are not holding any shares except Mr. Puneet Dhawan & Mr. Sanchit Hans, who is holding 14091400 & 100 Equity share of the Company.

c) None of the employees are relative of any director. There is no Manager in terms of the Section 2(53) of the Companies Act, 2013.

d) Terms of employment of all the aforesaid employees are permanent in nature.

Regd. Office:

A-16 G T Karnal Road Industrial Area,

Delhi-110033

CIN: L24239DL2019PLC354658

Date: 03rd September, 2026

Place: New Delhi

**For and on behalf of the Board of Directors
of KRM Ayurveda Limited**

**Sd/-
(Puneet Dhawan)
Managing Director
DIN: 08553667**

ANNEXURE-F

Annual Report on Corporate Social Responsibility (CSR) Activities

(Pursuant to Section 135 of the Companies Act, 2013 and its Rules)

1. A Brief Outline of Company's CSR Policy is mentioned in the Directors' Report.

2. The Composition of CSR Committee, as on 31st March, 2026, is as follows:

Sl. No	Name of Directors	Designation /Nature of Directorship	Number of meetings of CSR Committee held during the year (2025-26)	Number of meetings of CSR Committee attended during the year (2025-26)
1	NA	NA	NA	

3. Provide the web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the board are disclosed on the website of the company- NA

4. Provide the details of Impact assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social Responsibility Policy) Rules, 2014 - Not Applicable.

5. Details of the amount available for set off in pursuance of sub-rule (3) of rule 7 of the Companies (Corporate Social Responsibility Policy) Rules, 2014 and amount required for set off for the financial year, if any-

Sl. No.	Financial year	Amount available for set-off from preceding financial years (in Rs)	Amount required to be set-off for the financial year, if any (in Rs)
1	2022-23	0	0
2	2023-24	0	0
3	2024-25	0	0
Total		0	0

6. Average Net Profit of the Company for last three financial years: Rs. 1036.07 lakhs

7. (a) Two percent of average net profit of the company as per Section 135(5): Rs. 20.72 lakhs

(b) Surplus arising out of the CSR projects or programmes or activities of the previous financial years: Nil (c)

Amount required to be set off for the financial year: Nil

(d) Total CSR obligation for the financial year (7a+7b- 7c): Rs. 20.72 lakhs

8. (a) CSR amount spent or unspent for the financial year:

Total Amount Spent for the Financial year. (in Rs.)	Amount Unspent (in Rs.)				
	Total Amount transferred to Unspent CSR Account as per section 135(6).		Amount transferred to any fund specified under Schedule VII as per second proviso to section 135(5).		
	Amount	Date of Transfer	Name of the Fund	Amount	Date of Transfer
2,157,041	-	-	NA	NA	NA

(B) Details of CSR spent on On-going projects for the Financial year

Sr. No.	Name of the project	Item from the list of Activities in Schedule VII to the ACT	Local Area (Yes/No)	Location of the project		Project duration	Amount allocated for the project (in Rs.)	Amount spent in the current Financial year (in Rs.)	Amount transferred to Unspent CSR Account for the project as per Section 135(6) (in Rs.)	Mode of Implementation - Direct (Yes/No)	Mode of Implementation -Through Implementing Agency		
				State	District						Name	CSR registration No.	
													Not applicable

Details of CSR amount spent against other than ongoing projects for the Financial year:

Sr. No.	Name of the project	Item from the list of activities in Schedule VII to the Act	Local Area (Yes/No.)	Location of the project		Amount spent for the project (in Rs.)	Mode of Implementation on Direct (Yes/no.)	Mode of Implementation through Implementing Agency.	
				State	District			Name	CSR registration No.
1	Livelihood Enhancement Projects	Promoting Education (Distribution of Study Material)	Yes	Delhi	Delhi	600,000	No	Sarvhit Vidhut Jan Kalyan Samiti	CSR00060599
2	Healthcare & Poverty	Hospital Construction & Other Allied Charitable Activities	Yes	Delhi	Delhi	1,400,000	No	Samarpan Charitable Trust	CSR00006298
3	Livelihood Enhancement Projects	Promoting Education	Yes	Delhi	Delhi	157,041	Yes	-	-

(D) Amount Spent in Administrative Overheads: Nil

(E) Amount Spent on Impact Assessment: Not Applicable

(F) Total Amount spent for the Financial year (8b+8c+8d+8e): Nil

(G) Excess amount for set off, if any

Sr. No.	Particulars	Amount (in Rs.)
1	Two percent of average net profit of the company as per section 135(5)	20.72 lakhs
2	Total amount spent for the Financial year	21.57 lakhs
3	Excess amount spent for the Financial year [(ii)-(i)]	0.85 lakhs
4	Surplus arising out of the CSR projects or programmes or activities of the previous Financial years, if any	Nil
5	Amount available for set off in succeeding Financial years [(iii)-(iv)]	0.85 lakhs

(A) Details of Unspent CSR amount for the preceding Three Financial years

Sr. No.	Preceding Financial Year.	Amount transferred to Unspent CSR Account under section 135 (6) (in Rs.)	Amount spent in the reporting Financial year (in Rs.).	Amount transferred to any fund specified under Schedule VII as per section 135(6), if any.			Amount remaining to be spent in succeeding Financial years. (in Rs.)
				Name of the Fund	Amount (in Rs).	Date of transfer.	
1	2023-24	750,000	-	-	-	-	750,000
2	2024-25	1,148,575	496,955	-	-	-	651,620
3	2025-26	168,000	-	-	-	-	168,000

(B) Details of CSR amount spent in the Financial year for ongoing projects of the preceding Financial year(s)

Sr. No.	Project ID	Name of the project.	Financial year in which the project was commenced	Project duration	Total amount allocated for the project (in Rs.)	Amount spent on the project in the reporting Financial Year (in Rs.).	Cumulative amount spent at the end of reporting Financial Year. (in Rs.)	Status of the project - Completed /Ongoing.
Not applicable								

10. In case of acquisition of Capital Asset, furnish the details relating to the asset so created or acquired through CSR spent in the Financial year (asset wise details): - Not Applicable

- a) Date of creation or acquisition of the capital asset(s)
- b) Amount of CSR spent for creation or acquisition of capital asset
- c) Details of the entity or public authority or beneficiary under whose name such capital asset is registered, their address etc.
- d) Provide details of the capital asset(s) created or acquired (including complete address and location of the capital asset)

11. Specify the reason(s), if the company has failed to spend two per cent of the average net profit as per section135(5): - Not Applicable

12. The CSR Committee confirms that the implementation and monitoring of CSR Policy is in compliance with the CSR objectives and Policy of the Company.

13. The CSR Committee has not been constituted as the Company is not required to constitute a CSR Committee in accordance with the applicable provisions of Section 135 of the Companies Act, 2013 and the rules made thereunder. The functions and responsibilities relating to CSR, to the extent applicable, are discharged by the Board of Directors.

**For and on behalf of the Board of Directors
of KRM Ayurveda Limited**

Date: 03rd September, 2026

Place: New Delhi

**Sd/-
Mr. Puneet Dhawan
Managing Director
(DIN:08553667)**

**Sd/-
Mr. Sanchit Hans
Whole-Time Director
(DIN:09228549)**

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

(Pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To
The Members
KRM Ayurveda Limited
A-16, GT Karnal Road,
Industrial Area,
New Delhi – 110033

I have examined the relevant registers, records, forms, returns and disclosures received from the Directors of KRM Ayurveda Limited having CIN - L24239DL2019PLC354658 and having registered office at A-16 G T Karnal Road Industrial Area, Delhi-110033 (hereinafter referred to as 'the Company'), produced before me by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In my opinion and to the best of my information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to me by the Company & its Officers, I hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ended March 31, 2026 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs, or any such other Statutory Authority.

S.N.	Name	DIN	Date of Appointment
1	Puneet Dhawan	8553667	3/9/2019
2	Sanchit Hans	9228549	24/2/2023
3	Tanya Dhawan	8553668	30/9/2024
4	Vandana Gupta	13488	21/1/2025
5	Laxmi	10717921	21/1/2025

Ensuring the eligibility of for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For Amit K Mangla & Company
Practicing Company Secretaries

Sd/-
Amit Kumar Mangla
(Proprietor)
FCS No. 11450, CP No.: 23164
Peer Review Certificate No. 4032/2023
UDIN: F011450H001356508

Date: 03.09.2026
Place: Faridabad

STATUTORY AUDIT REPORT

To the Members of KRM AYURVEDA LIMITED

Report on the Audit of the Financial Statements

Opinion

We have audited the Financial Statements of KRM AYURVEDA LIMITED, which comprise the balance sheet as at 31st March 2026, and the statement of Profit and Loss and statement of cash flows for the year then ended, and notes to the Audited Financial Statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Audited Financial Statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March 2026, its profit/loss and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAS) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Financial Statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Financial Statements of the current period. We have determined that there are no key audit matters to communicate in our report.

Information other than the Financial Statements and auditors' report thereon

The Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexures to Board's Report but does not include the Audited Financial Statements and our auditor's report thereon.

Our opinion on the Audited Financial Statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Financial Statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the Financial Statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Audited Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these Audited Financial Statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also

includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Financial Statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the Audited Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAS will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statement.

As part of an audit in accordance with SAS, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Audited Financial Statements, including the disclosures, and whether the Audited Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Financial Statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the 'Annexure A', a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

2. As required by Section 143 (3) of the Act, we report that:

a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

c) The Balance Sheet, the Statement of Profit and Loss and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.

d) In our opinion, the aforesaid Financial Statements comply with the Accounting Standards specified under Section 133 of the Act and rules made thereunder.

e) On the basis of the written representations received from the directors as on 31st March, 2026 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.

f) With respect to the adequacy of the internal financial controls with reference to Financial Statements of the Company and the operating effectiveness of such controls, refer to our separate Report in 'Annexure B'.

g) With respect to the matter to be included in the Auditor's Report under section 197(16), In our opinion and according to the information and explanations given to us, the remuneration paid by the Company to its directors during the current year is in accordance with the provisions of section 197 of the Act. The remuneration paid to any director is not in excess of the limit laid down under section 197 of the Act. The Ministry of Corporate Affairs has not prescribed other details under section 197(16) which are required to be commented upon by us. (applicable in case of Public Company).

h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

i. The Company does not have any pending litigations which would impact its financial position.

ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

iv. (a) The management has represented that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(b) The management has represented, that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

(c) Based on such audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material mis-statement.

v. No dividend has been declared or paid during the year by the company.

vi. Based on our examination which included test checks, the company has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of audit trail feature being tampered with.

For Shiv & Associates

(Chartered Accountants)

FRN: 009989N

CA Abhishek Vashisht

(Partner)

M.No-526307

UDIN: 26526307LDMZAW3933

Place: FARIDABAD

Date: 01st May, 2026

Annexure 'A'

The Annexure referred to in paragraph 1 of Our Report on "Other Legal and Regulatory Requirements".

We report that:

(i)(a)(A) The company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment;

(B) The company has maintained proper records showing full particulars of intangible assets;

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Property, Plant and Equipment have been physically verified by the management at reasonable intervals; no material discrepancies were noticed on such verification;

(c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of all the immovable properties (other than properties where the company is the lessee and the lease agreements are duly executed in favor of the lessee) disclosed in the Audited Financial Statements are held in the name of the company.

(d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the company has not revalued its Property, Plant and Equipment (including Right of Use assets) or intangible assets during the year. Accordingly, the reporting under Clause 3(i)(d) of the Order is not applicable to the Company.

(e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings have been initiated or are pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder.

(ii)(a) As explained to us & on the basis of the records examined by us, in our opinion, physical verification of inventory has been conducted at reasonable intervals by the management. In our opinion, the coverage and procedure of such verification by the management is appropriate. No discrepancy of 10% or more in the aggregate for each class of inventory were noticed on physical verification of stocks by the management as compared to book records.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the company has not been sanctioned during any point of time of the year, working capital limits in excess of five crore rupees, in aggregate, from banks or financial institutions on the basis of security of current assets and hence reporting under clause 3(ii)(b) of the Order is not applicable.

(iii) According to the information and explanations given to us and on the basis of our examination of the records of the company, the company has not made investments in, nor provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties during the year. Accordingly, provisions of clause 3(iii)(a), 3(iii)(b), 3(iii)(c), 3(iii)(d), 3(iii)(e) and 3(iii)(f) of the Order are not applicable to the Company.

(a) According to the information and explanations given to us and on the basis of our examination of the records of the company, the investments made, guarantees provided, security given and the terms

and conditions of the grant of all loans and advances in the nature of loans and guarantees provided are not prima facie prejudicial to the company's interest.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, in the case of loans and advance in the nature of loan given, in our opinion the repayment of principal and payment of interest has been stipulated and the repayments or receipts have been regular.

(c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no overdue amounts for more than 90 days in respect of the loans granted to the parties.

(d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, no loan or advance in the nature of loan granted which has fallen due during the year, has been renewed or extended or fresh loans granted to settle the overdues of existing loans given to the same parties.

(e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the company has not granted any loans or advances in the nature of loans either repayable on demand or without specifying any terms or period of repayment.

(iv) According to the information and explanations given to us and on the basis of our examination of the records, in respect of loans, investments, guarantees, and security, provisions of section 185 and 186 of the Companies Act, 2013 have been complied.

(v) The company has not accepted any deposits or amounts which are deemed to be deposits covered under sections 73 to 76 of the Companies Act, 2013. Accordingly, clause 3(v) of the Order is not applicable.

(vi) As per information & explanation given by the management, maintenance of cost records has not been specified by the Central Government under sub-section (1) of section 148 of the Companies Act.

(vii)(a) According to the information and explanations given to us and on the basis Of our examination of the records of the company, the company is regular in depositing undisputed statutory dues including Goods and Services Tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues to the appropriate authorities. According to the information and explanation given to us there were outstanding statutory dues as on 31st March 2026 for a period of more than six months from the date they became payable. The list of Outstanding Statutory Dues are as follows:

Name of the Statue	Nature of the dues	Amount (Rs.)	Period to which the amount is related	Forum where dispute is Pending	Remark, if any
Income Tax Act 1961 (TDS)	Demand	Rs.1,49,300	2021-22	CPC	
Income Tax Act 1961 (TDS)	Demand	Rs.66,850	2022-23	CPC	
Income Tax Act 1961 (TDS)	Demand	Rs.6,510	2023-24	CPC	

(b) According to the information and explanations given to us and on the basis of our examination of the records of the company, there are statutory dues referred to in sub-clause (a) that have not been deposited.

(viii) According to the information and explanations given to us and on the basis of our examination of the records of the company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year.

(ix)(a) According to the of our examination of the records of the company, the company has not defaulted in repayment of loans or other borrowings or in the payment of interest According to the information and explanations given to us and on the basis of our examination of the records of the company, the company has not been declared a willful defaulter by any bank or financial institution or other lender.

(b) According to the information and explanations given to us by the management, the Company has utilized the money obtained by way of term loans during the year for the purposes for which they were obtained

(c) According to the information and explanations given to us and on an overall examination of the balance sheet of the Company, we report that no funds raised on short term basis have been used for long term purposes by the company.

(d) The Company does not hold any investment in any subsidiary, associate or joint venture (as defined under the Act) during the year ended 31st March, 2026. Accordingly, clause 3(ix)(e) is not applicable.

(e) The Company does not hold any investment in any subsidiary, associate or joint venture (as defined under the Act) during the year ended 31st March, 2026. Accordingly, clause 3(ix)(e) is not applicable.

(x)(a) The Company has raised funds during the year through an Initial Public Offer (IPO) . Accordingly, the provisions of clause 3(x)(a) of the Order are applicable, and the details of such fund-raising and their utilization have been appropriately disclosed in the financial statements refer note no.34(a) of financial statement.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the company has made private placement of shares during the year that have been appropriately disclosed in the financial statements refer note no.34(b) of financial statement.

(xi)(a) Based on examination of the books and records of the Company and according to the information and explanations given to us, no fraud by the company or any fraud on the company has been noticed or reported during the course of audit.

(b) According to the information and explanations given to us, no report under subsection (12) of section 143 of the Companies Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government;

(c) According to the information and explanations given to us by the management, no whistle-blower complaints had been received by the company

(xii) The company is not a Nidhi Company. Accordingly, clause 3(xii)(a), 3(xii)(b) and 3(xii)(c) of the Order is not applicable.

(xiii) In our opinion and according to the information and explanations given to us, all transactions with the related parties are in compliance with sections 177 and 188 of Companies Act, where applicable and the details have been disclosed in the Audited Financial Statements, as required by the applicable accounting standards.

(xiv)(a) In our opinion and based on our examination, the company does not require to have an internal audit system. Accordingly, clause 3(xiv)(a), of the Order is not applicable.

(b) Based on information and explanations provided to us, no internal audit had been conducted of the company. Accordingly, clause 3(xiv)(b), of the Order is not applicable

(xv) In our opinion and according to the information and explanations given to us, the company has not entered into any non-cash transactions with directors or persons connected with him and hence, provisions of Section 192 of the Companies Act, 2013 are not applicable to the Company.

(xvi)(a) In our Opinion and based on our examination, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934 (2 of 1934). Accordingly, clause 3(xvi)(a) of the Order is not applicable.

(b) In our Opinion and based on our examination, the Company has not conducted any Non-Banking Financial or Housing Finance activities without a valid Certificate of Registration (COR) from the Reserve Bank of India as per the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(b) of the Order is not applicable.

(c) In our Opinion and based on our examination, the Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable,

(d) According to the information and explanations given by the management, the Group does not have any CIC as part of the Group.

(xvii) Based on our examination, the company has not incurred cash losses in the financial year and in the immediately preceding financial year.

(xviii) There has been resignation of the statutory auditors during the year and we have taken into consideration the issues, objections or concerns raised by the outgoing auditors.

(xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the company as and when they fall due.

(xx) The provision of Corporate Social Responsibility under section 135 of the Companies Act, 2013 is applicable to the company and company has complied with such provisions. The amount of CSR spent is mentioned in the Note No. 7 of Notes on Accounts on Financial Statement,

Year	Opening Balance		Amount required to be Spent during the year	Amount additionally deposited in the account	Amount spent during the year		Closing Balance	
	With the Company	In Separate Company CSR Unspent			With the Company	In Separate Company CSR Unspent	With the Company	In Separate Company CSR Unspent
25-26		14.02		1.68				15.7

(xxi) The company is not required to prepare Consolidate financial statement hence this clause is not applicable.

For Shiv & Associates
(Chartered Accountants)
FRN: 009989N

CA Abhishek Vashisht
(Partner)
M.No-526307
UDIN: 26526307LDMZAW3933
Place: FARIDABAD
Date: 01st May, 2026

Annexure'B'

Report on Internal Financial Controls with reference to Audited Financial Statements

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act 2013 ("the Act")

We have audited the internal financial controls over financial reporting of KRM AYURVEDA LIMITED ("the Company") as of 31st March, 2026 in conjunction with our audit of the Audited Financial Statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute Of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the Audited Financial Statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of Audited Financial Statements for external purposes in accordance with generally accepted accounting principles, A company's internal financial control over financial reporting includes those policies and procedures that

1. pertain to the maintenance of records that, in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company;
2. provide reasonable assurance that transactions are recorded as necessary to permit preparation of Audited Financial Statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
3. provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the Audited Financial Statements,

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control Over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March, 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For Shiv & Associates
(Chartered Accountants)
FRN: 009989N

CA Abhishek Vashisht
(Partner)
M.No: 526307
UDIN: 26526307LDMZAW3933
Place: Faridabad
Date: 01st May, 2026

BALANCE SHEET

As at March 31, 2026

(All amounts in INR Lakhs unless otherwise stated)

Particulars	Note No.	31 MARCH, 2026	31 MARCH, 2025
A EQUITY AND LIABILITIES			
1 Shareholder's funds			
(a) Share capital	3	2,126.08	15.00
(b) Reserves and surplus (Retained Earnings)	4b	2,901.53	2,374.53
(c) Share Premium Account	4a	6,443.12	-
2 Share application money pending allotment		-	-
3 Non-currentliabilities			
(a) Long-term borrowings	5	-	1,862.81
(b) Deferred tax liabilities (net)		-	8.75
(c) Long Term Provisions		75.59	68.27
4 Currentliabilities			
(a) Short Term Borrowings	6	-	1,257.20
(b) Trade payables	7	319.17	533.06
(c) Other current liabilities	8	279.84	392.65
(d) Short-term provisions	9	82.27	166.29
TOTAL		12,227.60	6,678.56
B ASSETS			
1 Non-current assets			
(a) Property,Plantand Equipment	10	2,632.33	2,655.44
(b) Long term loans and Advances	11	131.52	109.33
(c) Deferred Tax Assets (net)		18.03	-
(d) Non-Current Investments	12	29.00	28.00
2 Current assets			
(a) Current Investments	13	3,801.40	852.00
(b) Inventories	14	902.85	769.64
(c) Trade receivables	15	2,272.72	1,212.83
(d) Cash and cash equivalents	16	946.88	204.05
(e) Short-term loans and advances	17	41.92	25.89
(f) Other Current Assets	18	1,450.96	821.38
TOTAL		12,227.60	6,678.56

See accompanying notes forming part of the Financial Statements.

In terms of our report attached.

For SHIV & ASSOCIATES

Chartered Accountants

Firm Reg. No. 009989N

(Abhishek Vashisht)

Partner

Membership No.: 526307

Place: Delhi

Date : 01-05-2026

UDIN : 26526307LDMZAW3933

for and on behalf of the board

PUNEET DHAWAN

Managing Director

DIN: 08553667

SANCHIT HANS

Whole Time Director

DIN: 09228549

AVTAR SINGH RANA

Chief Finance Officer

POOJA GARG

Company Secretary

M. No.: A51037

STATEMENT OF PROFIT AND LOSS ACCOUNT

For the year ended March 31, 2026

(All amounts in INR Lakhs unless otherwise stated)

Particulars	Note	31 MARCH, 2026	31 MARCH, 2025
I Revenue from operations (gross)	19	10,169.07	7,655.27
II Other Income	20	62.33	39.70
III Total Income(I+II)		10,231.40	7,694.97
IV Expenses			
(a) Cost of materials consumed	21	1,462.48	950.05
(b) Employee benefits expenses	22	2,107.61	1,908.26
(c) Finance costs	23	325.08	289.85
(d) Depreciation and amortisation expenses	10	114.37	104.39
(e) Other expenses	24	3,549.29	2,922.64
Total Expenses		7,558.83	6,175.19
V Profit before exceptional and extraordinary items and tax		2,672.57	1,519.78
VI Exception all tems & Extraordinary Items		-	-
VII Profit before Tax		2,672.57	1,519.78
VIII Tax Expense:			
(a) Current tax expense		687.35	397.57
(b) Taxation for earlier years		-	(2.24)
(c) Deferred tax		(26.78)	3.04
IX Profit for the year(VII-VIII)		2,012.00	1,121.41
X Earnings per share			
(1)Basic	31	9.46	747.61
(2)Diluted	31	9.46	747.61

See accompanying notes forming part of the Financial Statements.

In terms of our report attached.

For SHIV & ASSOCIATES

Chartered Accountants

Firm Reg. No. 009989N

for and on behalf of the board

(Abhishek Vashisht)

Partner

Membership No.: 526307

Place: Delhi

Date : 01-05-2026

UDIN : 26526307LDMZAW3933

PUNEET DHAWAN

Managing Director

DIN: 08553667

SANCHIT HANS

Whole Time Director

DIN: 09228549

AVTAR SINGH RANA

Chief Finance Officer

POOJA GARG

Company Secretary

M. No.: A51037

Statement of Cash Flow

For the year ended March 31, 2026

(All amounts in INR Lakhs unless otherwise stated)

	PARTICULARS	For the year ended 31 MARCH, 2026	For the year ended 31 MARCH, 2025
A	Cash Flow from Operating Activities:		
	Profit before tax	2,673	1,520
	Adjustments For :		
	Depreciation and Amortisation Expenses Provision for	114	104
	Gratuity (net of payment)	19	72
	Interest Expenses	269	212
	Interest Income	(62)	(40)
	Operating Profit before Working Capital Changes	3,012	1,869
	Adjustments For :		
	Increase / (Decrease) in Trade Payables	(214)	146
	Increase / (Decrease) in other Current liabilities	(113)	25
	(Increase) / Decrease in loans and advances	(16)	16
	(Increase) / Decrease in Trade Receivables	(1,060)	(659)
	(Increase) / Decrease in Inventories	(133)	(625)
	(Increase) / Decrease in Other Current Assets	(581)	(145)
	Cash generated from Operations	895	627
	Direct Taxes Paid (net of refunds)	(783)	(278)
	Net Cash from Operating Activities (A)	112	349
B	Cash Flow from Investing Activities:		
	Purchase of Property, plant and equipment	(91)	(472)
	Interest received	14	24
	(Investment in)/proceeds from purchase/sale of other bank deposits (net)	(2,950)	(277)
	Loan and Advances Given	(22)	(60)
	Net Cash used in Investment Activities (B)	(3,050)	(786)
C	Cash Flow from Financing Activities:		
	<i>Net Proceeds from issue of Share capital</i>	7,069	-
	Interest Paid	(269)	(212)
	Proceeds from Short Term Borrowings		1,452
	(Repayment) of Short Term Borrowings	(1,257)	(458)
	(Repayment) of Long Term Borrowings	(1,863)	(191)
	Net Cash from Financing Activities (C)	3,681	590
	Net Increase In Cash & Cash equivalents (A+B+C)	743	154
	Cash & Cash Equivalents at the beginning of the year	204	50
	Cash & Cash Equivalents at the end of the year	947	204
	Cash & Cash Equivalents at the end of the year comprises:		
	Cash on hand	352	119
	Balance with bank	595	85
		947	204

See accompanying notes forming part of the Financial Statements.

In terms of our report attached.

For SHIV & ASSOCIATES

Chartered Accountants

Firm Reg. No. 009989N

(Abhishek Vashisht)

Partner

Membership No.: 526307

Place: Delhi

Date : 01-05-2026

for and on behalf of the board

PUNEET DHAWAN

Managing Director

DIN: 08553667

AVTAR SINGH RANA

Chief Finance Officer

SANCHIT HANS

Whole Time Director

DIN: 09228549

POOJA GARG

Company Secretary

M. No.: A51037

Notes to Financial Statement

For the year ended March 31, 2026

(All amounts in INR Lakhs unless otherwise stated)

1. CORPORATE INFORMATION

KRM Ayurveda Limited was incorporated on 03rd September, 2019 under the Companies Act, 2013 having its registered office at A-16, GT Karnal Road, Industrial Area, Delhi-110033. The Company is engaged in manufacturing and trading of Ayurvedic products and providing ayurvedic therapies. Company has been converted in a Public Company on 23/12/2024.

2. BASIS OF PREPARATION OF FINANCIAL STATEMENTS

(SIGNIFICANT ACCOUNTING POLICIES & OTHER EXPLANATORY NOTES)

2.1 Basis of Preparation

The financial statements of the Company have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) to comply with the Accounting Standards specified under Section 133 of the Companies Act, 2013 read with the Companies (Accounting Standards) Rules, 2021, as amended ("Accounting Standards"), and other accounting principles generally accepted in India. The financial statements have been prepared on accrual basis under the historical cost convention and going concern basis. The accounting policies adopted in the preparation of the financial statements are consistent with those followed in the previous year.

The financial statements are presented in Indian Rupees (INR) & all values are rounded to nearest lacs, except where otherwise indicated.

All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in the Schedule III (as amended) to the Companies Act, 2013. Based on the nature of products and the time between the acquisition of assets for processing and their realization in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current and non-current classification of assets and liabilities.

2.2 Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in India requires the management to make estimates and assumptions that affect the reported amount of asset and liabilities as at Balance Sheet date, reported amount of revenue and expenses for the year and disclosures of contingent liabilities as at the Balance Sheet date. The estimates and assumptions used in the accompanying financial statement are based upon management's evaluation of relevant facts and circumstances as at the date of the financial statements. Actual results could differ from estimates.

2.3 Property, plant and equipment

Tangible assets

Property, plant and equipment (PPE) are carried at cost less accumulated depreciation and accumulated impairment losses if any. The cost of PPE comprises its cost of acquisition inclusive of freight, duties, taxes and incidental expenses upto the date the asset is ready for its intended use. PPE have been capitalized on the date the asset is ready for its intended use.

Depreciation and amortization

Depreciation/amortization is provided on a pro-rata basis on the written down value method /straight line method over the estimated useful lives of the assets indicated under Schedule II to the Companies Act, 2013. Assets less than Rs.5,000 are depreciated fully in the year of purchase. Leasehold improvement/structures are amortised over the duration of lease.

All assets except leasehold improvement, are depreciated on written down value method over the useful life prescribed in Schedule II of the Companies Act, 2013 after keeping residual value of 5% of total value of assets. Life of fixed assets are as follows:

Asset	Useful life
Computers	3 Years
Furniture and Fixtures	10 Years
Office Equipments	5 Years
Leasehold Improvement	Over the lease period

Gains or losses arising from derecognition of an asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in statement of profit and loss when asset is derecognized.

The residual value, useful lives and methods of depreciation of property plant & Equipment & intangible assets are reviewed at each financial year end.

2.4 Employee Benefits

Short-term and long-term employee benefits:

(i) Defined contribution plans

1. Provident Fund –

All employees (other than excluded employees) of the Company are entitled to receive benefits under the Provident Fund, which is a defined contribution plan. Both the employee and the employer make the monthly contribution to the plan at a predetermined rate (presently 12%) of the employee's basic salary. These contributions are made to the Fund administered and managed by Government of India. The Company's contribution to the scheme is expensed off in the Statement of Profit and Loss. The Company has no further obligations under the plan beyond its monthly contributions.

2. Employees' State Insurance Schemes

Some employees of the Company are covered under the Employees' State Insurance schemes, which is defined contribution schemes recognized and administered by the Government of India. The Company's contributions to these schemes are expensed in the Statement of Profit and Loss. The Company has no further obligations under the plan beyond its monthly contributions.

(ii) Defined benefit plan

Gratuity –

Gratuity is a post-employment defined benefit plan which is unfunded. The liability recognized in the Balance Sheet in respect of gratuity is a present value of the defined benefit obligation at the Balance Sheet date. The defined benefit obligation is calculated annually by an independent actuary using the Projected Unit Credit method. Actuarial gains or losses are charged or credited to the Statement of Profit and Loss in the year in which such gain or loss arise.

2.5 Foreign currency transactions

Initial recognition:

Foreign Currency transactions are recorded in the reporting currency, by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency on the date of the transaction.

Conversion:

Foreign currency monetary items are restated as at year-end using the closing rate. Non-monetary items which are carried at historical cost which are denominated in a foreign currency are reported using the exchange rates at the date of the transactions.

Exchange differences:

Exchange differences arising on the settlement of monetary items or restatement at rates different from those at which they were initially recorded during the year, or reported in previous financial statements, are recognized as income or expenses in the year in which they arise.

2.6 Leases

Operating Lease (As a Lessee):

Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to the Statement of Profit and Loss on a straight-line basis over the period of the lease.

Finance Lease (As a Lessee):

Assets leased by the Company in its capacity as a lessee, where substantially all the risks and rewards of ownership vest with the Company are classified as finance leases. Such leases are capitalised at the inception of the lease at the lower of the fair value and the present value of the minimum lease payments and a liability is created for an equivalent amount. Each lease rental paid is allocated between the liability and the interest cost so as to obtain a constant periodic rate of interest on the outstanding liability for each year.

2.7 Taxation

Tax expense comprises both current and deferred tax. The differences that result between the profit considered for income taxes and the profit as per the financial statements are identified, and thereafter a deferred tax asset or deferred tax liability is recorded for timing differences, namely the differences that originate in one accounting period and reverse in another, based on the tax effect of the aggregate amount of timing difference. The tax effect is calculated on the accumulated timing differences at the end of an accounting period based on enacted or substantively enacted regulations. Deferred tax assets in a situation where unabsorbed depreciation and carry forward business loss exists, are recognized only if there is virtual certainty supported by convincing evidence that sufficient future taxable income will be available against which such deferred tax asset can be realized. Deferred tax assets, other than in a situation of unabsorbed depreciation and carry forward business loss, are recognized only if there is reasonable certainty that they will be realized. Deferred tax assets are reviewed for the appropriateness of their respective carrying values at each reporting date. Deferred tax assets and deferred tax liabilities have been offset wherever the company has a legally enforceable right to set off current tax assets against current tax liabilities and where the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority.

The Company is required to pay Income Tax u/s 115BAA. Hence provision for Minimum Alternate Tax (MAT) are not applicable on the Company.

2.8 Revenue Recognition

Revenue is primarily derived from designing and development of computer softwares, IT enabled services, software training programmes and commission on trading of software licenses.

Arrangements with customers for software development and related services are either on a fixed-price, fixed-timeframe or on a time-and-material basis.

Revenue on time-and-material contracts are recognized as the related services are performed, and revenue from the end of the last billing to the Balance Sheet date is recognized as unbilled revenues. Revenue from fixed-price and fixed-timeframe contracts, where there is no uncertainty as to measurement or collectability of consideration, is recognized based upon the percentage of completion method. When there is uncertainty as to measurement or ultimate collectability, revenue recognition is postponed until such uncertainty is resolved.

Cost and earnings in excess of billings are classified as unbilled revenue while billings in excess of cost and earnings are classified as unearned revenue (deferred revenue). Provision for estimated losses, if any, on uncompleted contracts are recorded in the period in which such losses become probable based on the current estimates.

Revenue from client training, support and other services arising due to the sale of software products is recognized as the related services are performed.

The Company accounts for volume discounts and pricing incentives to customers as a reduction of revenue based on the rateable allocation of the discount / incentive amount to each of the underlying revenue transactions that result in progress by the customer towards earning the discount / incentive.

Revenue from sale of software licenses are record net of license fees paid by the company to the licensor.

Interest is recognized using the time-proportion method, basis taking into amount outstanding and applicable interest rate. Interest income is included under head other income in statement of profit and loss.

2.9 Impairment of assets

Assessment is done at each Balance Sheet date as to whether there is any indication that an asset (tangible and intangible) may be impaired. For the purpose of assessing impairment, the smallest identifiable group of assets that generates cash inflows from continuing use that are

largely independent of the cash inflows from other assets or groups of assets, is considered as a cash generating unit. If any such indication exists, an estimate of the recoverable amount of the asset/cash generating unit is made. Assets whose carrying value exceeds their recoverable amount are written down to the recoverable amount. Recoverable amount is higher of an asset's or cash generating unit's net selling price and its value in use. Value in use is the present value of estimated future cash flows expected to arise from the continuing use of an asset and from its disposal at the end of its useful life. Assessment is also done at each Balance Sheet date as to whether there is any indication that an impairment loss recognized for an asset in prior accounting periods may no longer exist or may have decreased.

2.10 Provisions, Contingent Liabilities and Contingent Assets

Provisions: Provisions are recognized when there is a present obligation as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and there is a reliable estimate of the amount of the obligation. Provisions are measured at the best estimate of the expenditure required to settle the present obligation at the Balance Sheet date and are not discounted to its present value.

Contingent liabilities: Contingent liabilities are disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the company or a present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount cannot be made, is termed as a contingent liability.

Contingent Assets: Contingent Assets are not recognised. However, when realisation of income is virtually certain, then the revalued asset is no longer a contingent asset and is recognised as an asset.

2.11 Onerous Contracts:

Provisions for onerous contracts are recognized when the expected benefits to be derived by the Company from a contract are lower than the unavoidable costs of meeting the future obligations under the contract.

The provision is measured at lower of the expected cost of terminating the contract and the expected net cost of fulfilling the contract.

2.12 Cash and cash equivalents (for the purpose of Cash Flow Statement)

Cash comprises cash on hand and balances with banks in current account and overdraft account (debit balances only).

2.13 Cash flow statement

Cash flows are reported using the indirect method, whereby profit before tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information.

2.14 Earning Per share (EPS)

Basic EPS is calculated by dividing the profit for the year attributable to ordinary equity shareholder of the company by the weighted average number of Equity shares outstanding during the year.

Diluted EPS is calculated by dividing the profit attributable to ordinary equity shareholders of the company by the weighted average number of Equity shares outstanding during the year plus the weighted average number of Equity shares that would be issued on conversion of all the dilutive potential Equity shares into Equity shares.

3. EQUITY SHARE CAPITAL

Particulars	As at 31 MARCH, 2026	As at 31 MARCH, 2025
(a) Authorised Equity shares of Rs.10/- each: 2,50,00,000 (March 31, 2025: 2,00,000)	2,500.00	20
(b) Issued, Subscribed and Paid up Equity shares of Rs.10/- each: 2,50,00,000 (March 31, 2025: 2,00,000)	2,126.08	15
Total	2,126.08	15

C. Reconciliation of shares outstanding at the beginning and at the end of the reporting year:

Particulars	As at 31 MARCH, 2026		As at 31 MARCH, 2025	
	No. of shares	Amount	No. of shares	Amount
Equity Shares				
Opening Balance at the beginning of the period	150,000	15	15,000	15
Share split during the period	-	-	135,000	-
Bonus issue during the period	14,850,000	1,485.00	-	-
Shares issued during the period - Private Placement	520,800	52.08	-	-
Shares issued during the period - IPO	5,740,000	574	-	-
Total	21,260,800	2,126.08	150,000	15

D. Rights, preferences and restrictions attached to shares

The Company has only one class of equity shares which were having par value of ₹ 100 per share. During the year the company has divided its existing shares of par value of ₹ 100 each into 10 shares of par value of ₹ 10 each. Each holder of equity shares is entitled to one vote per share. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all Preferential amounts, in proportion of their shareholding.

E. Details of shareholder holding more than 5% shares in the Company

Name of Shareholders	As at 31 MARCH, 2026		As at 31 MARCH, 2025	
	No. of Shares	% holding	No. of Shares	% holding
Puneet Dhawan	14,220,400	66.89%	149,000	99.33%

F. DETAILS OF PROMOTER SHAREHOLDING

Name of Shareholders	As at 31 MARCH, 2026		As at 31 MARCH, 2025	
	No. of Shares	% holding	No. of Shares	% holding
Equity shares of ₹ 10 each fully paid-up				
Puneet Dhawan	14,220,400	66.89%	149,000	99.33%
Tanya Dhawan	95,000	0.45%	950	0.63%
% change during the year/period				
Puneet Dhawan		-32.45%		-
Tanya Dhawan		-0.19%		-

4. RESERVES AND SURPLUS

Particulars	31 MARCH, 2026	31 MARCH, 2025
(A) Securities premium account		
Opening balance	-	-
Add: Security premium from issue of shares - Private Placement	348.94	-
Add: Security premium from issue of shares - IPO	7,175.00	-
Less: IPO Expenses	1,089.88	-
Add: Interest Income from Specific IPO Accounts	9.06	-
Closing balance	6,443.12	-
(B) Surplus / (Deficit) in Statement of Profit and Loss		
Opening balance	2,374.53	1,253.12
Add: Profit / (Loss) for the year	2,012.00	1,121.41
Less : Transfer to capital on account of Bonus Issue	1,485.00	
Closing balance	2,901.53	2,374.53
Total	9,344.65	2,374.53

5. LONG-TERM BORROWINGS

Particulars	31 MARCH, 2026	31 MARCH, 2025
SECURED LOANS	-	1,862.81
TOTAL	-	1,862.81

6. SHORT-TERM BORROWINGS

Particulars	31 MARCH, 2026	31 MARCH, 2025
SECURED LOANS	-	1,257.20
TOTAL	-	1,257.20

7. TRADE PAYABLES

Particulars	31 MARCH, 2026	31 MARCH, 2025
(i) Total outstanding dues of micro enterprises and small enterprises	10.45	39.35
(ii) Total outstanding dues for creditors other than micro enterprises and small enterprises	308.72	493.71
TOTAL	319.17	533.06

Trade Payables Ageing Schedule

Particulars	31 MARCH, 2026	31 MARCH, 2025
Undisputed Due to MSME		
Less than 1 Year	10.45	39.35
1-2 Years	-	-
2-3 Years	-	-
More than 3 Years	-	-
	10.45	39.35

Trade Payables Ageing Schedule

Particulars	31 MARCH, 2026	31 MARCH, 2025
Undisputed Other		
Less than 1 Year	306.72	492.46
1-2 Years	2	1.25
2-3 Years	-	-
More than 3 Years	-	-
	308.72	493.71

8. OTHER CURRENT LIABILITIES

Particulars	31 MARCH, 2026	31 MARCH, 2025
Advance From Customers	11.16	178.52
Salaries & Incentive Payable	152.98	144.8
Electricity Charges Payable	7.05	6.74
Delhi Jal Board	2.71	5.99
Director Remuneration Payable	6.52	8.65
Director Sitting Fees Payable	0.25	0.27
Audit Fees Payable	4.05	3.6
Telephone Expense Payable	1.43	-
BPA Charges Payable	5.63	-
Statutory Dues	74.05	30.06
CSR to Be Deposited in Fund	14.02	14.02
TOTAL	279.84	392.65

9. SHORT TERM PROVISIONS

Particulars	31 MARCH, 2026	31 MARCH, 2025
(a) Provision - for TAX		
Provision for Income Tax(Current Years)	67.00	162.89
(b) Provision- Gratuity	15.27	3.40
TOTAL	82.27	166.29

10. PROPERTY, PLANT & EQUIPMENT

For the Previous Year ended on March 31, 2026

Assets Category	GROSS BLOCK			DEPRECIATION			NET BLOCK	
Assets Category	Gross Value as on 01.04.2025	Addition During the year	Gross Value as on 31.03.2026	Depreciatio n Up to 31.03.2025	Depreciatio n During the Year	Total Depreciatio n As on 31- 03-2026	WDV as on 31st March 2025	WDV as on 31st March 2026
BUILDING	570.07	0	570.07	106.97	43.99	150.96	463.1	419.1
COMPUTERS AND DATA PROCESSING UNITS	115.71	10	125.71	102.64	11.57	114.21	13.07	11.5
FURNITURE & FIXTURE AND FITTINGS	48.6	11.68	60.28	19.24	8.69	27.93	29.36	32.35
LABORATORY EQUIPMENTS	1.43	0	1.43	0.53	0.16	0.7	0.89	0.73
MOTOR VEHICLES	37.7	1.04	38.74	10.08	7.34	17.42	27.62	21.32
OFFICE EQUIPMENTS	114.37	33.97	148.33	74.61	26.38	100.99	39.75	47.34
PLANT AND MACHINERY	96.26	34.58	130.84	27.03	16.24	43.27	69.23	87.57
LAND	2,012.41	0	2,012.41	0	0	0	2,012.41	2,012.41
GRAND TOTAL	2,996.54	91.26	3,087.80	341.1	114.37	455.47	2,655.44	2,632.33

For the Previous Year ended on March 31, 2025

Assets Category	GROSS BLOCK			DEPRECIATION			NET BLOCK	
Assets Category	Gross Value as on 01.04.2024	Addition During the year	Gross Value as on 31.03.2025	Depreciated on Up to 31.03.2024	Depreciated on During the Year	Total Depreciated on As on 31-03-2025	WDV as on 31st March 2024	WDV as on 31st March 2025
BUILDING	541.6	28.47	570.07	60.08	46.88	106.97	481.51	463.1
COMPUTERS AND DATA PROCESSING UNITS	105.75	9.96	115.71	90.73	11.92	102.64	15.02	13.07
FURNITURE & FIXTURE AND FITTINGS	41.24	7.36	48.6	10.88	8.36	19.24	30.36	29.36
LABORATORY EQUIPMENTS	1.43	0	1.43	0.34	0.2	0.53	1.09	0.89
MOTOR VEHICLES	5.75	31.95	37.7	1.93	8.15	10.08	3.82	27.62
OFFICE EQUIPMENTS	79.11	35.25	114.37	55.93	18.68	74.61	23.19	39.75
PLANT AND MACHINERY	60.9	35.36	96.26	16.83	10.19	27.03	44.06	69.23
LAND	1,688.37	324.04	2,012.41	0	0	0	1,688.37	2,012.41
GRAND TOTAL	2,524.13	472.41	2,996.54	236.72	104.39	341.1	2,287.42	2,655.44

11. LONG TERM LOANS AND ADVANCES

Particulars	31 MARCH, 2026	31 MARCH, 2025
Security Deposits	131.52	109.33
TOTAL	131.52	109.33

12. NON CURRENT INVESTMENTS

Particulars	31 MARCH, 2026	31 MARCH, 2025
Bank deposits with maturity more than one year		
Bank Guarantee	26.00	28.00
EMD	1.00	-
Fixed Deposit against Credit Card	2.00	-
TOTAL	29.00	28.00

13. CURRENT INVESTMENTS

Particulars	31 MARCH, 2026	31 MARCH, 2025
Bank deposits with maturity less than one year		
Bank Deposits	4.40	100.00
Bank Deposits - Earmarked/restricted #	3797.00	752.00
TOTAL	3,801.40	852.00

These deposits have been kept against bank guarantee provided to various government authorities for empanelment of Company's Ayurvedic Treatments Centres and against Credit Card.

Bank Deposits – Earmarked/restricted includes an amount of 3,045.00 lac for Bank Deposits of IPO Proceeds earmarked as per the objects of Prospectus.

14. INVENTORIES

Particulars	31 MARCH, 2026	31 MARCH, 2025
(at lower of cost or net realizable value)		
Finished Goods	817.17	498.74
Raw Material (including Packing Material)	85.68	270.90
TOTAL	902.85	769.64

15. TRADE RECEIVABLES

Particulars	31 MARCH, 2026	31 MARCH, 2025
Secured, considered good	-	-
Unsecured, considered good	2272.72	1212.83
Doubtful	-	-
TOTAL	2272.72	1212.83

Trade Receivables Ageing Schedule

Particulars	31 MARCH, 2026	31 MARCH, 2025
Undisputed trade receivable (considered good)		
Less than 6 Months	1812.67	902.60
6 months - 1 year	232.06	195.82
1-2 Years	118.29	114.40
2-3 Years	109.70	-
More than 3 Years	-	-
	2272.72	1212.83

* There are no disputed trade receivables.

16. CASH AND CASH EQUIVALENTS

Particulars	31 MARCH, 2026	31 MARCH, 2025
(A) Cash In Hand	351.40	118.65
(B) Bank Balance	52.93	85.40
(C) Bank Balance in OD Accounts	542.55	-
TOTAL	946.88	204.05

17. SHORT-TERM LOANS AND ADVANCES

Particulars	31 MARCH, 2026	31 MARCH, 2025
Advances to Suppliers	27.16	17.68
Loans & Advances to Employees	14.76	8.21
TOTAL	41.92	25.89

18. OTHER CURRENT ASSETS

Particulars	31 MARCH, 2026	31 MARCH, 2025
Balance with government authorities	1335.49	767.76
CSR Fund lien in bank	15.70	5.22
Other Current Assets	99.78	48.40
TOTAL	1,450.96	821.38

19. REVENUE FROM OPERATIONS

Particulars	31 MARCH, 2026	31 MARCH, 2025
Sale of Products	4,701.02	4,923.30
Sale of Services	5,468.05	2,731.97
TOTAL	10,169.07	7,655.27

20. OTHER INCOME

Particulars	31 MARCH, 2026	31 MARCH, 2025
Interest Income	62.33	39.70
TOTAL	62.33	39.70

21. COST OF MATERIALS CONSUMED

Particulars	31 MARCH, 2026	31 MARCH, 2025
Opening Stock	769.64	144.76
Add: Purchases	1,595.68	1,574.93
Less: Closing Stock	902.85	769.64
Cost of material consumed	1,462.48	950.05

22. EMPLOYEE BENEFIT EXPENSES

Particulars	31 MARCH, 2026	31 MARCH, 2025
Salaries and Wages	1661.43	1346.67
Salary Incentives	248.71	268.59
EPF Employer's Contribution	38.13	42.86
ESI Employer's Contribution	5.37	5.11
Gratuity Expense	19.19	71.67
Other Benefits to Staff	24.79	10.59
Director Remuneration	104.35	157.59
Staff Welfare	5.64	5.18
Total	2,107.61	1,908.26

23. FINANCE COST

Particulars	31 MARCH, 2026	31 MARCH, 2025
Bank Charges	23.34	36.69
Interest on Bank Loan	171.27	184.67
Interest on Unsecured Loan	4.03	-
Interest on OD	93.38	27.76
Interest on TDS	0.54	40.73
Interest on Income Tax	32.52	-
Total	325.08	289.85

24. OTHER EXPENSES

Particulars	31 MARCH, 2026	31 MARCH, 2025
Advertisement Expenses	1,340.59	1,519.78
Annual Maintenance Charges	3.32	4.32
Audit Fees	2.5	2.5
Biomedical Waste Expense	12.03	-

Books & Periodicals	-	0.03
Business Promotion Expenses	4.02	4.42
Car Rental Expenses	19.71	20.16
Commission Expenses	14.05	9.06
Computer Expenses	5.82	3.11
Conference & Seminars Expenses	10.36	3.85
Consumable Expenses	172.88	35.38
Conveyance Expenses	18.36	4.89
Courier Charges	191.33	193.48
CSR Expense	21.57	11.49
Director Sitting Fees	1.08	0.27
Discount On Sale	0.80	0.97
Diwali Expenses	9.67	2.01
Domain Charges	5.22	4.69
ECHS/CGHS/Insurance Charges	31.12	77.12
Electricity Expenses	99.74	85.22
Fee Rates & Taxes	52.92	26.03
Fluctuation Charges	2.99	-
Freight & Cartage Expenses	4.69	2.85
FOC Expenses	-	0.83
Fuel Charges	1.29	0.01
Generator Expenses	6.87	4.32
GST & Interest Paid 2021-22	2.45	1.15
GST Refund Disallowed	6.58	-
Insurance Charges	0.94	4.60
IPD Food Expenses	139.27	80.14
ITC Reversal	-	0.53
ITC Reversal (Common ITC)	287.48	138.08

ITC Write Off.	6.39	-
Lab Testing Expenses	5.98	4.13
Late Fee On GST	0.42	0.63
Laundry Expenses	13.83	9.29
Loan Processing Fee	-	5.11
Membership Charges	3.49	0.68
Miscellaneous Expenses	5.97	11.66
Office Expenses	17.12	27.68
Packing & Labour Charges	0.28	-
Penalty On GST 2021-22	0.09	-
Pest Control Expenses	4.19	2.09
Printing & Stationary Expenses	18.31	9.44
Professional Fee	128.62	77.99
Property Tax Expenses	8.68	2.06
Recruitment Expenses	0.94	0.84
Rent Expenses	511.34	299.97
Rent For Generator	19.27	8.82
Repair & Maintenance Charges	32.99	11.40
Ro Rental Expenses	2.47	2.01
Round Off	(0.01)	0.09
Royalty Charges	125.00	100.00
Running & Maintenance Of Vehicle	4.61	4.34
Security Service Charges	48.98	1.58
Short & Excess	-	0.01
Software Expenses	13.56	11.84
Tax Audit Fees	2.00	1.50
TDS Write Off	-	11.77
Telephone And Internet Expenses	64.17	47.02
Therapy Expense	2.00	-
Tour & Travelling Expenses	37.67	29.34
Water Charges	1.26	0.08
Total	3,549.29	2,922.64

25. AUDITOR'S REMUNERATIONS

Particulars	31 MARCH, 2026	31 MARCH, 2025
Statutory Audit	2.50	2.50
Tax Audit	2.00	1.50
Total	4.50	4.00

26. CORPORATE SOCIAL RESPONSIBILITY EXPENSES

Particulars	31 MARCH, 2026	31 MARCH, 2025
a) Gross amount required to be spent by the Company during the year	20.72	18.99
b) Gross amount provided for CSR activities	21.57	11.49
c) Amount spent during the year	21.57	4.97
d) Shortfall at the end of the year	-	6.52
e) Total of previous years shortfall and lying in CSR Unspent Account	14.02	7.50
f) Reason for shortfall	NA	#
g) Nature of CSR activities Promoting preventive health care and education.		
# Ongoing Project to be spent before 31.03.2028		

Particulars	31 MARCH, 2026	31 MARCH, 2025
a) Opening Balances		
With the Company	-	-
In Separate Company CSR Unspent	14.02	7.50
b) Amount required to be Spent during the year	-	11.49
c) Amount additionally deposited in the account	1.68	-
d) Amount spent during the year		
With the Company	-	2.69
In Separate Company CSR Unspent	-	2.28

With the Company	-	-
In Separate Company CSR Unspent	15.70	14.02

27.DEFERRED TAX ASSETS AND LIABILITIES

As per Accounting Standard 22 on "Accounting for Taxes on Income" issued by Institute of Chartered Accountants of India (ICAI), the Deferred Tax Assets (DTA) comprises of the following:

Tax effect of items constituting Deferred Tax Asset	31 MARCH, 2026	31 MARCH, 2025
(i) Excess of WDV as per Income Tax Act over Book Value	13.2	-8.75
(ii) Provision for Retirement Benefits	4.83	-
DTA / (DTL)	18.03	-8.75

28.SEGMENT REPORTING

The Company's operates only in one business segment viz. "Trading of Ayurvedic Medicines and providing Ayurvedic Therapies". Accordingly, there are no separate reporting segments as per Accounting Standard 17 "Segment Reporting".

29.MSME DISCLOSURES

Dues to micro and small enterprises pursuant to section 22 of the Micro and small Enterprises Development Act (MSMED), 2006 to the extent information available with the management is given below:

Particulars	As at 31 MARCH, 2026	As at 31 MARCH, 2025
(i) The principal amount and the interest due thereon (to be shown separately) remaining unpaid to any supplier at the end of each accounting year	10	39

-Principal	-	-
-Interest		-
(ii) The amount of interest paid by the buyer in terms of section 16 of the Micro, Small and Medium Enterprises Development Act (MSMED), 2006 along with the amount of payment made to the supplier beyond the appointed day during each accounting year	-	-
(iii) The amount of interest due and payable for the period (where the principal has been paid but interest under the Micro, Small and Medium Enterprises Development Act (MSMED), 2006 not paid)	-	-
(iv) The amount of interest accrued and remaining unpaid at the end of accounting year	-	-
(v) The amount of further interest remaining due and payable even in the succeeding years until such date when the interest dues above are actually paid to the small enterprise for the purpose of disallowance of a deductible expenditure u/s 23 of the Micro, Small and Medium Enterprises Development Act (MSMED), 2006	-	-

30. EARNINGS PER SHARE

Particulars	Units	As at 31 MARCH, 2026	As at 31 MARCH, 2025
a. Amount used as numerator Profit available to Equity Shareholders		2,012	1,121
b. Shares used as Denominator*	No.	21,260,800	150,000
c. Basic & Diluted earning per Share.	Rs./ Share	9.46	747.61
d. Nominal Value per share	Rs.	10	10

* During the year the company has issued share capital through private placement and IPO refer Note 3 for details

* The Company has not issued any Dilutive equity shares and therefore Diluted EPS is same as Basic EPS.

31. DETAILS OF OPENING STOCK, TURNOVER, PURCHASES, CLOSING STOCK

Particulars	Year Ended	Export Services	Export goods	Raw Material	Finished Goods	Services
Opening Stock	31 Mar 2026	-	-	271	499	-
	31 Mar 2025	-	-	22	122	-
Purchase	31 Mar 2026	-	-	1,563	33	-
	31 Mar 2025	-	-	870	705	-
Sales/Dispatch	31 Mar 2026	1,447	1,380	-	3,321	4,021
	31 Mar 2025	-	2,587	-	2,336	2,732
Manufactured/ consumed	31 Mar 2026	-	-	1,748	-	-
	31 Mar 2025	-	-	621	-	-
Closing Stock	31 Mar 2026	-	-	86	817	-
	31 Mar 2025	-	-	271	499	-

32.RELATED PARTY DISCLOSURE**A. Names of related parties and nature of relationship:**

Description of relationship	Names of related parties
Key Management Personnel (KMP)	i) Puneet Dhawan (Managing Director) ii) Tanya Dhawan (Director) iii) Sanchit Hans (Whole Time Director) iv) Pooja Garg (Compliance Officer) v) Avtar Singh Rana (Chief Financial Officer)
Relative of KMP	i) Som Dev Dhawan ii) Aruna Dhawan
Entities in which KMP/Relatives of KMP can exercise significant influence	i) Karma Ayurveda ii) Blue Bliss Motels & Resorts iii) Karma Life Care LLC iv) Karma Online Services LLC

B. Transactions with related parties are as follows:

Particular	Key Management Personnel (KMP)	Entities in which KMP/Relatives of KMP can exercise significant influence	Relative of KMP	Total
(i) Salary, allowances and bonus				
March 31, 2026	119.37			119.37
March 31, 2025	109.22		49.00	158.22
(ii) Consultancy				
March 31, 2026	12.00			12.00
March 31, 2025	6.00			6.00
(iii) Purchase (PPE)				
March 31, 2026	-	-	-	-
March 31, 2025	6.50	14.14	-	6.50
(iv) Royalty				
March 31, 2026	125.00	-	-	125.00
March 31, 2025	118.00	-	-	118.00
(v) Rent / Lease Rent				
March 31, 2026	164.26		18.05	182.31
March 31, 2025	164.26		18.05	182.31
(vi) Sale of Goods & Services				

March 31, 2026		2,603.04		2,603.04
March 31, 2025		2,351.90		2,351.90
(vii) Interest Paid				
March 31, 2026	4.03	-	-	4.03
March 31, 2025	-	-	-	-
(viii) Borrowings received/(repaid) - Net				
March 31, 2026	4.03	-	-	4.03
March 31, 2025	-	-	-	-

C. Balances outstanding are as follows:

Particular	Key Management Personnel (KMP)	Entities in which KMP/Relatives of KMP can exercise significant influence	Relative of KMP	Total
(i) Salary, allowances and bonus payable				
March 31, 2026	6.52			6.52
March 31, 2025	6.76		1.90	8.66
(iv) Expenses Payable				
March 31, 2026	1.13	-	-	1.13
March 31, 2025	98.00	-	-	98.00
(v) Trade Advances Received				
March 31, 2026		10.29		10.29
March 31, 2025		177.08		177.08

33. DISCLOSURE ON SIGNIFICANT RATIOS

Particular	31 MARCH, 2026	31 MARCH, 2025	% Change
Current Ratio	13.82	1.65	735.64%
Debt-Equity Ratio	-	1.31	-100.00%
Debt Service Coverage Ratio	9.57	6.60	44.97%
Return on Equity Ratio	0.29	0.61	-52.65%
Inventory turnover ratio	12.16	16.74	-27.37%
Trade Receivables turnover ratio	5.83	8.67	-32.68%
Trade payables turnover ratio	3.74	3.42	9.39%

Net capital turnover ratio	1.16	4.98	-76.63%
Net profit ratio	19.79%	14.65%	35.06%
Return on Capital employed	26.13%	42.56%	-38.59%
Return on Investment	31.71%	32.70%	-3.01%

Reason for changes in ratio (more than 10%):

- i. Debt Equity ratio – Decrease in ratio on account of decrease in Debt and increase in Shareholders Equity.
- ii. Debt Service Coverage Ratio - Increase in ratio on account of increase in Profits during the year and decreased in debts.
- iii. Return on Equity Ratio - Decrease in ratio on account of increase in shareholders equity during the year.
- iv. Inventory turnover ratio - Decrease in ratio on account of increase in average inventory holding during the year.
- v. Trade Receivables turnover ratio – Decrease in ratio on account of increase in amount due from the Government Panel Debtor.
- vi. Net capital turnover ratio – Decrease in ratio on account of increase in Company net working capital position (Current Asset - Current Liability).
- vii. Net profit ratio - Increase in ratio on account of increase in revenue and margin.
- viii. Return on Capital employed - Decrease in ratio on account of increase in shareholders equity during the year.

Methodology:

1. Current Ratio = Current Asset/Current Liability
2. Debt-Equity Ratio = Total Debt/(Total Equity)
3. Debt Service Coverage Ratio = EBITDA/Finance Cost
4. Return on Equity Ratio = Profit After Tax/Total Equity
5. Inventory Turnover Ratio = Purchase/Inventory
6. Trade Receivable Turnover Ratio = Revenue from Operations/Trade Receivable
7. Trade Payable Turnover Ratio = Purchase/Trade Payable
8. Net Capital Turnover Ratio = Revenue from Operations/ (Current Asset - Current Liability)
9. Net Profit Ratio = Profit After Tax/Revenue from Operations
10. Return on Capital Employed = EBIT/(Total Equity)
11. Return on Investment = EBIT/(Total Assets)

34. (A) DETAILS OF IPO PROCEEDS AND UTILIZATION

i. PROCEEDS FROM THE IPO

The company has completed its initial public offer (IPO) of 57,40,000 equity shares of face value of Rs. 10 each at an issue price of Rs. 135 per share amounting to Rs. 7,749/- Lakhs. The equity shares of the company were listed on NSE Emerge platform (India Limited ("NSE Emerge")) on 29th of January, 2026.

Sr. No.	Particulars	Proposed	Actual	Deviation (₹ Cr)
1	Proceeds from the issue of Shares	77.49	77.49	-
2	Less: Issue related expenses	11.57	11.77	-0.20
	Net Proceeds from IPO	65.92	65.72	-0.20

ii. DETAILS OF UTILIZATION PROCEEDS FROM IPO

Sr.No	Object of Issue (As per Prospectus)	Proposed	Utilised	Balance amount kept in Bank as Fixed Deposits	Deviation
1	Capital Expenditure for Construction and Development of Telemedicine Operational Facilities	13.67		13.66	0.01
2	Purchase of CRM Software and Hardware Infrastructure	1.42		1.42	0.00
3	Human Resources	5.44		5.43	0.01
4	Repayment / Prepayment of Loan	12.50	12.50		0.00
5	To meet Working Capital requirements of the Company	22.90	22.77		0.13
6	General Corporate Purposes	9.99		9.94	0.05
	Total	65.92	35.27	30.45	0.20

(B) DETAILS OF PRIVATE PLACEMENT DURING THE YEAR

The company has issued and subscribed private placement of 5,20,800 equity shares of face value of Rs. 10 each at an issue price of Rs. 77 per share amounting to Rs. 401.01/- Lakhs.

(C) DETAILS OF BONUS ISSUE DURING THE YEAR

The company has issued and subscribed private placement of 1,48,50,000 equity shares of face value of Rs. 10 each at an issue price of Rs. 10 per share amounting to Rs. 1,485.00/- Lakhs.

35. DISCLOSURES PURSUANT TO ACCOUNTING STANDARD-15 "EMPLOYEE BENEFITS"

a. Defined Benefit Plan and other Employee Benefit

- Disclosure relating to Defined Benefit Plan (Gratuity) as per Actuarial Valuation as on 31st March, 2026 using Projected Unit Credit Method and recognized in the Financial Statements in respect of Employees Benefits Schemes.

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Expenses recognized in the statement of Profit & Loss		
Current Service Cost	23.52	21.34
Interest Cost	5.05	2.79
Expected Return on Plan Assets	-	-
Net Actuarial (Gains) / Losses	(9.38)	9.04
Past Service cost	-	-
Total Expense	19.19	33.17
Net Liability recognized in the balance sheet		
Present value of Defined Benefit Obligation as at 31st March, 2025	90.86	71.67
Fair Value of plan assets as at 31st March, 2025	-	-

Funded status {Surplus / (Deficit)}	(90.86)	(71.67)
Net liability as at 31 March, 2025	(90.86)	(71.67)
Change in Defined Benefit Obligations (DBO)		
Present value of Defined Benefit Obligation at the beginning of the year	71.67	38.50
Current Service Cost	23.52	21.34
Interest Cost	5.05	2.79
Past Service cost	-	-
Net Actuarial (Gains) / Losses	(9.38)	9.04
Benefit Paid	-	-
Present value of Defined Benefit Obligation at the end of the year	90.86	71.67
Change in Assets		
Plan assets at the beginning of period	-	-
Expected Return on Plan Assets	-	-
Contributions by Employer	-	-
Actual benefits paid	-	-
Actuarial Gains / (Losses) on Plan Assets	-	-
Plan assets at the end of the year	-	-
Actual Return on Plan Assets	-	-

ii. The actuarial calculations used to estimate commitments and expenses are based on the following assumption which if changed, would affect the commitments size, funding requirement and expenses.

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
	7.90%	7.04%
Discount Rate (%)	-	-
Expected rate of return on plan assets (%)	-	-
Mortality rate	IALM (2012-14)	IALM (2012-14)
Withdrawal rate		
Upto 30 Years	25.00%	25.00%
From 31 to 44 Years	25.00%	25.00%
Above 44 Years	5.00%	5.00%
Salary Escalation (%)	5.00%	5.00%

The estimates of future salary increases in actuarial valuations, take account of inflation, seniority, promotion and other relevant factors such as supply and demand factors in employment market.

iii. The disclosures included above are limited to the extent provided by the actuary.

b. Defined Contribution Plan

In accordance with the Employee's Provident Fund and Miscellaneous Provisions Act, 1952 and Employees' State Insurance Act, 1948, eligible employees of the Company are entitled to receive benefits in respect of provident fund and Employees State Insurance,

a defined contribution plan, in which both employees and the Company make monthly contributions at a specified percentage of the covered employees' salary. The contributions, as specified under the law, are made to the employee provident fund organization (EPFO) and Employees' State Insurance Act, 1948 (ESI).

The total expenses recognised in the statement of profit and loss during the year on account of defined contribution plans towards Employees Provident Fund (EPFO) amounted to ₹ 38.13 Lakhs (PY: ₹ 42.86 Lakhs) and towards Employees State Insurance (ESIC) amounted to ₹ 5.36 Lakhs (PY: ₹ 5.11 Lakhs).

36. ADDITIONAL REGULATORY INFORMATION NOT DISCLOSED ELSEWHERE IN THE FINANCIAL STATEMENTS:

- a) The Company does not have any Benami property and no proceedings have been initiated on or are pending against the Company for holding benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and Rules made thereunder.
- b) The Company has not been declared a 'Willful Defaulter' by any bank in accordance with the guidelines on willful defaulters issued by the Reserve Bank of India.
- c) The Company has complied with the number of layers prescribed under clause (87) of section 2 of the Act read with Companies (Restriction on number of Layers) Rules, 2017.
- d) The Company does not have any charges or satisfaction which is yet to be registered with Registrar of Companies beyond the statutory period.
- e) The Company does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).
- f) The Company has not revalued its property, plant and equipment or intangible assets or both during the current or previous year.
- g) The Company has not entered into any scheme of arrangement which has an accounting impact on current or previous financial year.
- h) The Company has not traded or invested in crypto currency or virtual currency during the current or previous year.
- i) The Company does not have any transactions with companies struck off under section 248 of the Companies Act, 2013 or section 560 of Companies Act, 1956.
- j) The Company has not advanced or loaned or invested funds to any other persons or entities, including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
 - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
 - (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries

k) The Company has not received any fund from any persons or entities, including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries A

l) The company does not have any long term contracts including derivatives contracts for which there are any material foreseeable losses.

M) There are no amounts which were required to be transferred to the investor Education and protection fund by the company.

37. The books of account along with other relevant records and papers of the Company are maintained in electronic mode. These are readily accessible in India at all times on a server physically located in India. The backup of books of account along with other relevant records and papers are maintained on a daily basis.

38. As per the proviso to Rule 3(1) of Companies (Accounts) Rules, 2014, for the financial year commencing on or after the 1st day of April 2023, every company which uses accounting software for maintaining its books of account, shall use only such accounting software which has a feature of recording audit trail of each and every transaction, creating an edit log of each change made in the books of account along with the date when such changes were made and ensuring that the audit trail cannot be disabled.

The Company has used accounting software for maintaining its books of accounts, which have a feature of recording audit trail (edit log) facility, and the same is operated throughout the year for all relevant transaction recorded in the respective software. Further, from 1st April 2025 to 31st March 2026 where audit trail (edit log) facility was enabled, we did not come across any instance of the audit trail feature being tampered with during the year.

The Management has adequate internal controls over financial reporting which were operating effectively for the year ended March 31, 2026.

39. Any amount lower than a lac is appearing as 0.

40. Previous year figures have been regrouped/Reclassified where ever necessary to correspond to current year's classification.

For SHIV & ASSOCIATES

Chartered Accountants

Firm Reg. No. 009989N

for and on behalf of the board

(Abhishek Vashisht)

Partner

Membership No.: 526307

Place: Delhi

Date : 01-05-2026

UDIN :26526307LDMZAW3933

PUNEET DHAWAN

Managing Director

DIN: 08553667

SANCHIT HANS

Whole Time Director

DIN: 09228549

AVTAR SINGH RANA

Chief Finance Officer

POOJA GARG

Company Secretary

M. No.: A51037

